<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0905245269
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Camzyos
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MAVACAMTEN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        6100.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PATHEON INC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PATHEON INC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 530]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Salehiya Trading Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Bristol Myers Squibb Pharma EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QC01EB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What CAMZYOS is and what it is used for</p><p><strong>What CAMZYOS is</strong></p><p>CAMZYOS contains the active substance mavacamten. Mavacamten is a reversible cardiac myosin inhibitor, meaning that it changes the action of the muscle protein myosin in heart muscle cells.</p><p><strong>What CAMZYOS is used for</strong></p><p>CAMZYOS is used to treat adults with a type of heart disease called obstructive hypertrophic cardiomyopathy (oHCM).</p><p>&nbsp;</p><p><strong>About obstructive hypertrophic cardiomyopathy</strong></p><p>Hypertrophic cardiomyopathy (HCM) is a condition where the walls of the left heart chamber (ventricle) contract harder and become thicker than normal. As the walls thicken they can block (obstruct) the flow of blood out of the heart and can also make the heart stiff. This obstruction makes it more difficult for blood to flow into and out of the heart and be pumped to the body with each heartbeat, a condition known as obstructive hypertrophic cardiomyopathy (oHCM). Symptoms of oHCM are: chest pain and shortness of breath (especially with physical exercise); tiredness, abnormal heart rhythms, dizziness, feeling that you are about to faint, fainting (syncope) and swelling of the ankles, feet, legs, abdomen and/or veins in the neck.</p><p>&nbsp;</p><p><strong>How CAMZYOS works</strong></p><p>CAMZYOS works by reducing excess contraction of the heart and the obstruction to blood flow to the body. As a result, it may improve your symptoms and your ability to be active.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What you need to know before you take CAMZYOS</p><p><strong>Do not take CAMZYOS if:</strong></p><p>&sect;&nbsp;&nbsp;&nbsp; you are allergic to mavacamten or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>&sect;&nbsp;&nbsp;&nbsp; you are pregnant or a woman of childbearing potential not using effective contraception.</p><p>&sect;&nbsp;&nbsp;&nbsp; if you are taking medicines which may increase the level of CAMZYOS in your blood such as:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; oral medicines to treat fungal infections such as itraconazole, ketoconazole, posaconazole, voriconazole,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines to treat bacterial infections such as the antibiotics clarithromycin,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines to treat HIV infection such as cobicistat, ritonavir,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; certain medicines to treat cancer such as ceritinib, idelalisib, tucatinib.</p><p>Ask your doctor if the medicine you are taking prevents you from taking mavacamten. See section &ldquo;Other medicines and CAMZYOS&rdquo;.</p><p><strong>Warnings and precautions</strong></p><p>&nbsp;</p><p><strong>Routine tests</strong></p><p>Your doctor will assess how well your heart is working (your heart function) using an echocardiogram (an ultrasound test that takes images of your heart) before your first dose and regularly during treatment with CAMZYOS. It is very important to keep these echocardiogram appointments, because your doctor needs to check the effect of CAMZYOS on your heart. Your treatment dose may need to be adjusted to improve your response or to reduce side effects.</p><p>If you are a woman who could become pregnant your doctor may perform a pregnancy test before starting treatment with CAMZYOS.</p><p>Your doctor may do a test to check how this medicine is broken down (metabolised) in your body as this may be used to guide your CAMZYOS treatment (see section&nbsp;3).</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist straight away:</strong></p><p>&sect;&nbsp; <strong>if you get any of these symptoms during your treatment with </strong><strong>CAMZYOS:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; new or worsening shortness of breath,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness,</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations (a forceful heartbeat that may be rapid or irregular), or</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; leg swelling.</p><p>These could be signs and symptoms of systolic dysfunction, a condition where the&nbsp;heart&nbsp;cannot pump with enough force, which can be life-threatening and lead to heart failure.</p><p>&sect;&nbsp; <strong>if you develop</strong> a serious infection or irregular heart beat (arrhythmia) as this could increase your risk of developing heart failure.</p><p>Your doctor may need to do additional tests of your heart function, interrupt the treatment or change your dose, depending on how you feel.</p><p>Women of childbearing potential</p><p>If used during pregnancy, CAMZYOS can harm the unborn baby. Before you start treatment with CAMZYOS your doctor will explain the risk to you and ask you to do a pregnancy test in order to ensure that you are not pregnant. Your doctor will give you a card which explains why you should not become pregnant while taking CAMZYOS. It also explains what you should do to avoid becoming pregnant while you are taking CAMZYOS. You must use effective contraception during treatment and for 6&nbsp;months after stopping treatment (see section &ldquo;Pregnancy and breast-feeding&rdquo;).</p><p>If you do become pregnant while taking CAMZYOS, tell your doctor straight away. Your doctor will stop treatment (see &ldquo;If you stop taking CAMZYOS&rdquo; in section&nbsp;3).</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children (aged below 18&nbsp;years) because the effectiveness and safety of CAMZYOS have not been studied in children and adolescents.</p><p><strong>Other medicines and CAMZYOS</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This is because some other medicines can affect the way CAMZYOS works.</p><p>Some medicines can increase the amount of CAMZYOS in your body and make it more likely for you to get side effects that may be severe. Other medicines can reduce the amount of CAMZYOS in your body and may reduce its beneficial effects.</p><p>In particular, before taking CAMZYOS tell your doctor or pharmacist if you are taking, have recently taken, or have changed the dose of any of the following medicines:</p><p>&sect;&nbsp; some medicines used to reduce the amount of acid your stomach produces (cimetidine, omeprazole, esomeprazole, pantoprazole)</p><p>&sect;&nbsp; antibiotics for bacterial infections (such as clarithromycin, erythromycin)</p><p>&sect;&nbsp; medicines used to treat fungal infections (such as itraconazole, fluconazole, ketoconazole, posaconazole and voriconazole)</p><p>&sect;&nbsp; medicines used to treat depression (such as fluoxetine, fluvoxamine, citalopram)</p><p>&sect;&nbsp; medicines for HIV infections (such as ritonavir, cobicistat, efavirenz)</p><p>&sect;&nbsp; rifampicin (an antibiotic for bacterial infections like tuberculosis)</p><p>&sect;&nbsp; apalutamide, enzalutamide, mitotane, ceritinib, idelalisib, ribociclib, tucatinib (medicines used to treat certain types of cancer)</p><p>&sect;&nbsp; medicines for fits (seizures) or epilepsy (such as carbamazepine and phenytoin, phenobarbital, primidone)</p><p>&sect;&nbsp; St. John&rsquo;s wort (a herbal medicine for depression)</p><p>&sect;&nbsp; medicines that affect your heart (such as beta blockers and calcium channel blockers e.g. verapamil and diltiazem)</p><p>&sect;&nbsp; medicines that make your heart more resistant to abnormal activity (such as sodium channel blockers e.g. disopyramide)</p><p>&sect;&nbsp; ticlopidine (a medicine to prevent heart attack and stroke)</p><p>&sect;&nbsp; letermovir (a medicine to treat cytomegalovirus infections)</p><p>&sect;&nbsp; norethindrone (a medicine to treat various menstrual problems)</p><p>&sect;&nbsp; prednisone (steroid).</p><p>&nbsp;</p><p>If you take or have taken any of these medicines, or have changed the dose, your doctor needs to closely monitor you, may need to change your dose of CAMZYOS, or consider alternative treatments.</p><p>&nbsp;</p><p>If you are not sure whether you are taking any of the medicines mentioned above, ask your doctor or pharmacist before taking CAMZYOS. Before stopping or changing the dose of a medicine or starting a new medicine, tell your doctor or pharmacist.</p><p>&nbsp;</p><p>Do not take any of the above medicines occasionally or once in a while (not on a regular schedule) since that could change the amount of CAMZYOS in your body.</p><p><strong>CAMZYOS with food and drink</strong></p><p>You should use caution when drinking grapefruit juice while on treatment with CAMZYOS as it may change the amount of CAMZYOS in your body.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast‑feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Do not take CAMZYOS during pregnancy, for 6&nbsp;months before getting pregnant, or if you are a woman who could become pregnant and you are not using effective contraception. CAMZYOS may cause harm to your unborn baby. If you are a woman who could become pregnant, your doctor will inform you about this risk and will check if you are pregnant before starting treatment and regularly during treatment. Your doctor will give you a card which explains why you should not become pregnant while taking CAMZYOS. If you become pregnant, think you may be pregnant or planning to become pregnant while taking CAMZYOS, tell your doctor right away.</p><p><u>Breast-feeding</u></p><p>It is not known if CAMZYOS passes through breastmilk. You must not breast‑feed while taking CAMZYOS.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Mavacamten may have a small effect on your ability to drive and use machines. If you feel dizzy while taking this medicine, do not drive a vehicle, cycle or use any tools or machines.</p><p>&nbsp;</p><p><strong>CAMZYOS contains sodium</strong></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per capsule, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to take CAMZYOS</p><p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended starting dose is 2.5&nbsp;mg or 5&nbsp;mg taken by mouth once daily. Your doctor may do a test to check how this medicine is broken down (metabolised) in your body. The result may guide your CAMZYOS treatment. If you have liver problems, your doctor may also prescribe a reduced starting dose.</p><p>&nbsp;</p><p>Your doctor will monitor how well your heart is working while you are taking CAMZYOS using echocardiograms and may change your dose (increase, lower, or temporarily stop) based on the results.</p><p>&nbsp;</p><p>Your doctor will tell you how much CAMZYOS to take.</p><p>Your doctor will prescribe you a single daily dose of either 2.5&nbsp;mg, 5&nbsp;mg, 10&nbsp;mg or 15&nbsp;mg. The maximum single dose is 15&nbsp;mg once daily.</p><p>&nbsp;</p><p>Always take CAMZYOS as prescribed by your doctor.</p><p>&nbsp;</p><p>The first echocardiogram will be done before you start treatment, and then again during follow-up visits at week&nbsp;4, 8 and 12 to assess your response to CAMZYOS. Routine echocardiograms will then be done every 12&nbsp;weeks. If your doctor changes your dose of CAMZYOS at any point, an echocardiogram will be done 4&nbsp;weeks afterwards to make sure you are receiving a beneficial dose.</p><p><strong>Taking this medicine</strong></p><p>&sect;&nbsp; Swallow the capsule whole with a glass of water at about the same time each day.</p><p>&sect;&nbsp; You can take the medicine with food or between meals.</p><p>&nbsp;</p><p><strong>If you take more CAMZYOS than you should</strong></p><p>If you take more capsules than you should, contact your doctor or go to a hospital straight away if you have taken 3 to 5&nbsp;times the recommended dose. If possible, take the medicine pack and this leaflet with you.</p><p>&nbsp;</p><p><strong>If you forget to take CAMZYOS</strong></p><p>If you forget to take CAMZYOS at the usual time, take your dose as soon as you remember on the same day and take your next dose at the usual time the next day. Do not take a double dose to make up for a forgotten capsule.</p><p>&nbsp;</p><p><strong>If you stop taking CAMZYOS</strong></p><p>Do not stop taking CAMZYOS unless your doctor tells you to. If you wish to stop taking CAMZYOS, notify your doctor to discuss the best way to do so.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Possible side effects</p><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>Tell your doctor or pharmacist immediately</strong> if you get any of these symptoms during treatment with CAMZYOS:</p><p>&sect;&nbsp; new or worsening shortness of breath, chest pain, tiredness, palpitations (a forceful heartbeat that may be rapid or irregular), or leg swelling. These could be signs and symptoms of systolic dysfunction (a condition where the heart cannot pump with enough force), which can lead to heart failure and be life-threatening. <em>(Common side effect)</em></p><p>&nbsp;</p><p><strong>Very common (may affect more than&nbsp;1 in 10&nbsp;people)</strong></p><p>&sect;&nbsp; dizziness</p><p>&sect;&nbsp; difficulty breathing</p><p>&nbsp;</p><p><strong>Common (may affect up to 1 in 10&nbsp;people)</strong></p><p>&sect;&nbsp; fainting</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. By reporting side effects you can help provide more information on the safety of this medicine</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; How to store CAMZYOS</p><p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and carton after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store at or below 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What CAMZYOS contains</strong></p><p>&sect;&nbsp; The active substance(s) is mavacamten. Each hard capsule contains either 2.5&nbsp;mg, 5&nbsp;mg, 10&nbsp;mg or 15&nbsp;mg of mavacamten.</p><p>&sect;&nbsp; The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>capsule content:</u> silica, colloidal hydrated, mannitol (E421), hypromellose (E464), croscarmellose sodium (E468, see section&nbsp;2 &ldquo;CAMZYOS contains sodium&rdquo;), magnesium stearate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>capsule shell:</u></p><p>CAMZYOS 2.5&nbsp;mg hard capsules</p><p>gelatin, titanium dioxide (E171), iron oxide black (E172), iron oxide red (E172)</p><p>CAMZYOS 5&nbsp;mg hard capsules</p><p>gelatin, titanium dioxide (E171), iron oxide yellow (E172)</p><p>CAMZYOS 10&nbsp;mg hard capsules</p><p>gelatin, titanium dioxide (E171), iron oxide red (E172)</p><p>CAMZYOS 15&nbsp;mg hard capsules</p><p>gelatin, titanium dioxide (E171), iron oxide black (E172)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>printing ink:</u> iron oxide black (E172), shellac (E904), propylene glycol (E1520), ammonia solution, concentrated (E527), potassium hydroxide (E525</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What CAMZYOS looks like and contents of the pack
	The CAMZYOS 2.5 mg, approximately 18.0 mm in length, hard capsules (capsules) have a light purple opaque cap and white opaque body imprinted in black ink with “2.5 mg” on the cap and “Mava” on the body.
	The CAMZYOS 5 mg, approximately 18.0 mm in length, hard capsules (capsules) have a yellow opaque cap and white opaque body imprinted in black ink with “5 mg” on the cap and “Mava” on the body.
	The CAMZYOS 10 mg, approximately 18.0 mm in length, hard capsules (capsules) have a pink opaque cap and white opaque body imprinted in black ink with “10 mg” on the cap and “Mava” on the body.
	The CAMZYOS 15 mg, approximately 18.0 mm in length, hard capsules (capsules) have a grey opaque cap and white opaque body imprinted in black ink with “15 mg” on the cap and “Mava” on the body.

The hard capsules are packaged in aluminium foil blisters containing 14 hard capsules.

Each pack contains either 14 or 28 hard capsules. Not all pack sizes may be marketed.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Bristol-Myers Squibb Pharma EEIG</p><p>Plaza 254</p><p>Blanchardstown Corporate Park&nbsp;2</p><p>Dublin 15, D15 T867</p><p>Ireland</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Patheon Inc.</p><p>2100 Syntex Court</p><p>Mississauga, Ontario</p><p>L5N 7K9, Canada</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in Aug 2024
Approved by SFDA on 5th May 2025
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p dir="RTL">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; معلومات عن كامزايوس ودواعي استخدامه</p><p dir="RTL"><strong>معلومات عن كامزايوس</strong></p><p dir="RTL">يحتوي كامزايوس على المادة الفعالة مافاكامتن. مافاكامتن هو مثبط انعكاسي للميوزين القلبي، ويعني ذلك أنه يغير من أداء بروتين الميوزين العضلي داخل خلايا عضلة القلب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>دواعي استخدام كامزايوس</strong></p><p dir="RTL">يُستخدم كامزايوس لعلاج البالغين المصابين بنوع من أمراض القلب يعرف باعتلال عضلة القلب التضخمي الانسدادي.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>معلومات عن اعتلال عضلة القلب التضخمي الانسدادي</strong></p><p dir="RTL">اعتلال عضلة القلب التضخمي الانسدادي هو حالة تنقبض فيها جدران الغرفة اليسرى للقلب (البطين) انقباضاً أشد وتصبح أكثر سمكاً من الطبيعي. وكلما زاد سُمك الجدران، كلما أعاقت تدفق الدم خارج القلب ويمكن أن تجعل القلب متصلباً. يؤدي هذا الانسداد إلى صعوبة أكبر في تدفق الدم داخل القلب وخارجه، وضخه إلى باقي أعضاء الجسم مع كل دقة، وهي حالة تعرف باعتلال عضلة القلب التضخمي الانسدادي. تشمل أعراض اعتلال عضلة القلب التضخمي الانسدادي ما يلي: ألم بالصدر وضيق التنفس (أثناء ممارسة التمارين الرياضية خاصةً)؛ والإجهاد، وعدم انتظام ضربات القلب، والدوار، والشعور أنك على وشك الإغماء، والغشيان (الإغماء)، وتورم الكاحلين، و/أو القدمين، و/أو الساقين، و/أو البطن و/أو أوردة الرقبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة عمل كامزايوس</strong></p><p dir="RTL">يعمل كامزايوس على تقليل الانقباض الزائد للقلب والانسداد أمام وصول الدم إلى باقي الجسم. ونتيجة لذلك، قد يحسن من أعراضك وقدرتك على أداء أنشطتك.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ما يجب معرفته قبل تناوُل كامزايوس</p><p dir="RTL"><strong>لا تتناول كامزايوس في الحالات التالية:</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك حساسية تجاه مافاكامتن أو أي من المكونات الأخرى لهذا الدواء (المدرجة في القسم 6).</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ حاملاً أو في سن الحمل ولا تستخدمين وسيلة فعالة لمنع الحمل.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أدوية قد ترفع من مستوى كامزايوس في دمك مثل الأدوية التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الفموية لعلاج العدوى الفطرية مثل إيتراكونازول، أو كيتوكونازول، أو بوساكونازول، أو فوريكونازول،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو بعض الأدوية المستخدمة لعلاج العدوى البكتيرية مثل المضاد الحيوي كلاريثروميسين،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو بعض الأدوية المستخدمة لعلاج عدوى فيروس نقص المناعة البشرية مثل كوبيكستات وريتونافير،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو بعض الأدوية المستخدمة لعلاج السرطان مثل سيرتينيب، أو إيديلاليسيب أو توكاتينيب.</p><p dir="RTL">استشر طبيبك عما إذا كان الدواء الذي تتناوله يتعارض مع تناوُل مافاكامتن. يُرجى الاطلاع على القسم &quot;كامزايوس والأدوية الأخرى&quot;.<strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الاختبارات الروتينية</strong></p><p dir="RTL">سيقيم طبيبك حالة قلبك (أداء قلبك) بإجراء تخطيط صدى القلب (فحص بالموجات فوق الصوتية يلتقط صوراً لقلبك)، قبل تناولك أول جرعة من كامزايوس، وبانتظام أثناء تناوله. ومن المهم أن تحتفظ بمواعيد إجراء تخطيط صدى القلب، لأن طبيبك سيحتاجها للتحقق من تأثير كامزايوس على قلبك. وقد يحتاج طبيبك إلى تعديل جرعتك العلاجية لتحسين استجابتك أو لتقليل الآثار الجانبية.</p><p dir="RTL">إذا كنتِ سيدة في سن الحمل، فسيُجري لكِ طبيبك اختبار حمل قبل البدء في العلاج باستخدام كامزايوس.</p><p dir="RTL">قد يُجري طبيبك اختباراً لمراجعة امتصاص (استقلاب) جسمك لهذا الدواء، لأن هذا الاختبار قد يستخدم في توجيه علاجك باستخدام كامزايوس (اطلع على القسم 3).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلاني على الفور في الحالات التالية:</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا شعرت بأي من الأعراض التالية أثناء العلاج باستخدام كامزايوس:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق تنفس جديد أو متفاقم،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو ألم بالصدر،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو إرهاق،</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أو خفقان (ضربات قلب قوية قد تكون سريعة أو غير منتظمة)، أو</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الساق.</p><p dir="RTL">قد تكون هذه علامات وأعراض قصور القلب الانقباضي، وهي حالة يعجز فيها القلب عن ضخ الدم بقوة كافية، التي يمكن أن تهدد الحياة وتؤدي إلى فشل القلب.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا تعرضت</strong> لعدوى خطيرة أو اضطراب بضربات القلب، لأن هذه الحالات قد تزيد من خطر إصابتك بفشل القلب.</p><p dir="RTL">قد يحتاج طبيبك إلى إجراء اختبارات إضافية لوظيفة القلب لديك، وإيقاف العلاج أو تغيير جرعته، حسب شعورك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">النساء في سن الإنجاب</p><p dir="RTL">إذا استخدمتِ كامزايوس أثناء الحمل، فمن الممكن أن يؤذي جنينك. قبل البدء في العلاج باستخدام كامزايوس، سيشرح لكِ طبيبِك مخاطره عليكِ وسيطلب منك إجراء اختبار حمل للتأكد من أنكِ لست حاملاً. سيعطيكِ طبيبِك بطاقة تشرح لماذا يجب أن تمنعي الحمل أثناء تناوُل كامزايوس. كما تشرح ما يجب عليكِ فعله لتجنب الحمل أثناء تناولِك كامزايوس. يجب أن تستخدمي وسيلة فعالة لمنع الحمل أثناء تلقي العلاج ولمدة 6 أشهر بعد إيقافه (يُرجى الاطلاع على القسم &quot;الحمل والرضاعة الطبيعية&quot;).</p><p dir="RTL">إذا أصبحتِ حاملاً أثناء تناوُل كامزايوس، فأخبري طبيبِك فوراً. وسيوقف طبيبِك العلاج (يُرجى الاطلاع على &quot;إذا توقفتِ عن تناول كامزايوس&quot; في القسم 3).</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">يجب عدم إعطاء هذا الدواء للأطفال (تحت سن 18 عاماً) لأن فعالية كامزايوس وأمانه لم تُختبَرا على الأطفال والمراهقين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأدوية الأخرى وكامزايوس</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلاني إذا كنت تتناول أي أدوية أخرى، أو تناولتها مؤخراً أو قد تتناولها. لأن بعض الأدوية الأخرى قد تؤثر على فعالية كامزايوس.</p><p dir="RTL">قد تزيد بعض الأدوية كمية كامزايوس التي يمتصها جسمك، مما يجعلك أكثر عرضة للإصابة بآثار جانبية والتي قد تكون شديدة. وقد تقلل أدوية أخرى من كمية كامزايوس في جسمك، مما قد يقلل من آثاره المفيدة.</p><p dir="RTL">أخبر طبيبك أو الصيدلاني قبل تناوُل كامزايوس خاصةً إذا كنت تتناول أحد الأدوية التالية، أو تناولته مؤخراً أو غيرت جرعته:</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المستخدمة في خفض كمية الحمض الذي تفرزه معدتك (سيميتيدين، أو أوميبرازول، أو إيزوميبرازول أو بانتوبرازول)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية للعدوى البكتيرية (مثل كلاريثروماسين أو إريثرومايسين)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج العدوى الفطرية (مثل إيتراكونازول، أو فلوكونازول، أو كيتوكونازول، أو بوساكونازول أو فوريكونازول)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج الاكتئاب (مثل فلوكسيتين، أو فلوفوكسامين، أو سيتالوبرام)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المستخدمة لعلاج فيروس نقص المناعة البشرية (مثل ريتونافير، أو كوبيكستات أو إيفافيرنز)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبيسين (مضاد حيوي يستخدم لعلاج العدوى البكتيرية مثل مرض السُّل)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أبالوتاميد، أو إنزالوتاميد، أو ميتوتان، أو سيريتينيب، أو آيديلاليسيب، أو ريبوسيكليب، أو توكاتينيب (أدوية تُستخدم لعلاج بعض أنواع السرطان)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية النوبات أو الصرع (مثل كاربامازيبين، وفينيتوين، وفينوباربيتال وبريميدون)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون (دواء عشبي لعلاج الاكتئاب)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تؤثر على القلب (مثل حاصرات بيتا وحاصرات قنوات الكالسيوم مثل فيراباميل وديلتيازيم)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تجعل القلب أكثر مقاومة للنشاط غير الطبيعي (مثل حاصرات قنوات الصوديوم، مثل ديسوبيرامايد)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيكلوبيدين (دواء يمنع السكتة القلبية والسكتة الدماغية)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ليتيرموفير&nbsp;(دواء يعالج عدوى الفيروس المضخِّم للخلايا)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نوريثيستيرون (دواء يعالج العديد من مشكلات الطمث)</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بريدنيزون (دواء ستيرويدي).</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تتناول أياً من هذه الأدوية أو تناولته، أو غيرت الجرعة، فسيحتاج طبيبك إلى متابعتك عن كُثب، وقد تضطر إلى تغيير الجرعة التي تتناولها من كامزايوس، أو التفكير في علاجات بديلة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;إذا لم تكن متأكداً ما إذا كنت تتناول أياً من الأدوية المذكورة أعلاه، فاستشر طبيبك أو الصيدلاني قبل تناوُل كامزايوس. قبل التوقف عن تناوُل أي دواء أو تغيير جرعته أو البدء في تناوُل دواء جديد، أخبر طبيبك أو الصيدلاني.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتناول أياً من الأدوية المذكورة أعلاه بين الحين والآخر أو مرة واحدة كل فترة (دون جدول منظم)، لأن ذلك قد يغير من كمية كامزايوس التي يمتصها جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كامزايوس مع الطعام والشراب</strong></p><p dir="RTL">يجب أن تتوخى الحذر عند تناول عصير الجريب فروت أثناء تلقي علاج كامزايوس لأنه قد يغير من كمية كامزايوس التي يمتصها جسمك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">إذا كنتِ حاملاً أو‑مرضعة، أو تشكين أنكِ حاملاً أو تخططين للحمل، فاستشيري طبيبِك قبل تناوُل هذا الدواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">لا تتناولي كامزايوس أثناء الحمل، أو قبل الحمل بستة أشهر، أو إذا كنتِ بسن الحمل ولا تستخدمين وسيلة فعالة لمنع الحمل. فقد يضر كامزايوس بجنينك.&nbsp; إذا كنتِ بسن الحمل، فسيخبرك طبيبك عن هذه المخاطر، وسيتأكد ما إذا كنتِ حاملاً قبل بدء العلاج، مع التأكد من ذلك بانتظام أثناء فترة العلاج. سيعطيكِ طبيبِك بطاقة تشرح لماذا يجب أن تمنعي الحمل أثناء تناوُل كامزايوس.&nbsp; إذا كنتِ حاملاً، أو تعتقدين أنك ربما تكونين حاملاً، أو تخططين للحمل أثناء تناوُل كامزايوس، فأخبري طبيبك على الفور.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">من غير المعروف ما إذا كان كامزايوس ينتقل خلال حليب الأم. يجب ألا تُرضعي‑ أثناء تناوُل كامزايوس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">&nbsp;قد يكون لمادة مافاكامتن تأثير قليل على قدرتك على القيادة واستخدام الآلات.&nbsp; إذا كنت تشعر بالدوخة أثناء تلقي هذا الدواء، فلا تقد سيارة، أو دراجة أو تستخدم أي أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>كامزايوس يحتوي على الصوديوم</strong></p><p dir="RTL">تحتوي كل كبسولة من هذا المنتج الدوائي على أقل من 1 ملي مول (23 ملجم)، مما يعني أنه في الأساس &quot;خالٍ من الصوديوم&quot;.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طريقة استعمال كامزايوس</p><p dir="RTL">تناوَل هذا الدواء وفقاً لإرشادات الطبيب تماماً. وإذا لم تكن متأكداً من طريقة استخدامه، فارجع إلى طبيبك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">جرعة البداية الموصى بها 2.5 ملجم أو 5 ملجم عن طريق الفم مرة واحدة يومياً. قد يُجري لك طبيبك اختباراً ليتأكد من طريقة امتصاص (استقلاب) جسمك لهذا الدواء. وقد تؤدي النتيجة إلى توجيه علاجك باستخدام كامزايوس. إذا كنت تعاني من مشكلات بالكبد، فقد يصف لك طبيبك أيضاً جرعة مخففة في البداية.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيتابع طبيبك طريقة عمل قلبك أثناء تناولك كامزايوس بإجراء تخطيط صدى القلب، وقد يغير الجرعة التي تتناولها (يزيدها، أو يقللها أو يوقفه مؤقتاً) وفقاً للنتائج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيخبرك طبيبك بجرعة كامزايوس التي ستتناولها.</p><p dir="RTL">سيصف لك طبيبك جرعة واحدة يومياً إما 2.5، أو 5، أو 10 أو 15 ملجم. أقصى جرعة واحدة مسموح بها هي 15 ملجم مرة واحدة يومياً.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول كامزايوس كما يصفه لك طبيبك دائماً.</p><p>&nbsp;</p><p dir="RTL">ستخضع لأول تخطيط لصدى القلب قبل بدء العلاج، ثم ستخضع له مرة أخرى أثناء زيارات المتابعة بالأسبوع الرابع، والثامن والثاني عشر لتقييم استجابتك لكامزايوس. ثم ستخضع لتخطيطات صدى القلب الروتينية كل 12 أسبوعاً. إذا غيّر طبيبك جرعتك من كامزايوس في أي وقت، فقد تخضع لتخطيط صدى القلب كل أربعة أسابيع بعد ذلك للتأكد من أنك تتلقى الجرعة المفيدة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>طريقة تناوُل هذا الدواء</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابتلع الكبسولة كاملة مع كوب من الماء في نفس الوقت تقريباً كل يوم.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول الدواء مع الطعام أو بين الوجبات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة تناوُل جرعة زائدة من كامزايوس</strong></p><p dir="RTL">إذا تناولت كبسولات أكثر مما ينبغي، فاتصل بطبيبك، أو توجه إلى المستشفى على الفور إذا تناولت 3 إلى 5 أضعاف الجرعة الموصى بها. ويجب أن تأخذ معك عبوة الدواء وهذه النشرة، إذا كان ذلك ممكناً.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في حالة نسيان تناوُل كامزايوس</strong></p><p dir="RTL">إذا نسيت أن تتناول كامزايوس في الوقت المعتاد، فتناوَل جرعتك بمجرد أن تتذكرها في نفس اليوم، وتناوَل الجرعة التالية في الوقت المعتاد باليوم التالي. لا تتناول جرعة مضاعفة لتعويض الكبسولة التي فاتتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول كامزايوس</strong></p><p dir="RTL">لا تتوقف عن تناوُل كامزايوس، إلا إذا طلب منك طبيبك. إذا رغبت في التوقف عن تناوُل كامزايوس، فأخبر طبيبك لمناقشة أفضل طريقة للقيام بذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية عن استخدام هذا الدواء، فاسأل طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p dir="RTL">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الآثار الجانبية المحتملة</p><p dir="RTL">قد يسبب هذا الدواء آثاراً جانبية كما هو الحال مع جميع الأدوية، على الرغم من أنه لا يُصاب الجميع بها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الخطيرة</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلاني على الفور،</strong> إذا أُصبت بأي من هذه الأعراض أثناء تناوُل كامزايوس:</p><p dir="RTL">&nbsp;&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق تنفس جديد أو متفاقم، أو ألم بالصدر أو إرهاق أو خفقان (ضربات قلب قوية قد تكون سريعة أو غير منتظمة)، أو تورم الساق. قد تكون هذه علامات وأعراض قصور القلب الانقباضي (حالة يعجز فيها القلب عن ضخ الدم بقوة كافية)، والذي يمكن أن يؤدي إلى فشل القلب ويهدد حياتك. <em>(الآثار الجانبية الشائعة)</em></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة جداً (قد تصيب أكثر من شخص واحد من بين كل عشرة أشخاص)</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوار</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة التنفس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>شائعة (قد تصيب ما يصل إلى شخص واحد من بين كل عشرة أشخاص)</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإغماء</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا أُصبت بأي آثار جانبية، فتحدث مع طبيبك. ويشمل ذلك أي آثار جانبية محتملة غير مدرجة في هذه النشرة. بالإبلاغ عن الآثار الجانبية، ستساعدنا على الحصول على المزيد من المعلومات حول سلامة هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طريقة تخزين كامزايوس</p><p dir="RTL">يُحفظ هذا الدواء بعيداً عن مرأى الأطفال ومتناولهم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية الموضح على الشريط أو العلبة الكرتون بعد كلمة EXP. يشير ﺗﺎريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُخزن في درجة حرارة 30 درجة مئوية أو أقل منها.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يجوز التخلص من أي أدوية في الفضلات السائلة أو المخلفات المنزلية. اسأل الصيدلاني عن طريقة التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات كامزايوس</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة (المواد) الفعالة هي مافاكامتن. تحتوي كل كبسولة صلبة على 2.5 ملجم، أو 5 ملجم، أو 10 ملجم أو 15 ملجم من مافاكامتن.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تتمثل المكونات الأخرى فيما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>تحتوي الكبسولة على:</u> سيليكا، غرواني مميه، مانيتول (E421)، هيدروكسي بروبيل ميثيل سيللوز (E464)، كروسكارميلوز الصوديوم (E468، انظر القسم 2 &quot;يحتوي كامزايوس على الصوديوم&quot;)، ستيرات المغنيسيوم</p><p dir="RTL"><em>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em><u>غلاف الكبسولة:</u></p><p dir="RTL">كبسولات كامزايوس 2.5 ملجم الصلبة</p><p dir="RTL">جيلاتين، ثنائي أكسيد التيتانيوم (E171)، أكسيد الحديد الأسود (E172)، أكسيد الحديد الأحمر (E172)</p><p dir="RTL">كبسولات كامزايوس 5 ملجم الصلبة</p><p dir="RTL">جيلاتين، ثنائي أكسيد التيتانيوم (E171)، أكسيد الحديد الأصفر (E172)</p><p dir="RTL">كبسولات كامزايوس 10 ملجم الصلبة</p><p dir="RTL">جيلاتين، ثنائي أكسيد التيتانيوم (E171)، أكسيد الحديد الأحمر (E172)</p><p dir="RTL">كبسولات كامزايوس 15 ملجم الصلبة</p><p dir="RTL">جيلاتين، ثنائي أكسيد التيتانيوم (E171)، أكسيد الحديد الأسود (E172)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>حبر الطباعة:</u> أكسيد الحديد الأسود (E172)، شيلاك (E904)، بروبلين جليكول (E1520)، محلول الأمونيا المركز (E527)، هيدروكسيد البوتاسيوم (E525)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل كامزايوس ومحتويات العبوة</strong></p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كامزايوس 2.5 ملجم، يبلغ طولها نحو 18.0 ملم، كبسولات صلبة بغطاء أرجواني فاتح غير شفاف وجسم أبيض غير شفاف مع طباعة &quot;2.5 ملجم&quot; على الغطاء وكلمة &quot;مافا&quot; على الجسم بحبر أسود.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كامزايوس 5 ملجم، يبلغ طولها نحو 18.0 ملم، كبسولات صلبة بغطاء أصفر غير شفاف وجسم أبيض غير شفاف مع طباعة &quot;5 ملجم&quot; على الغطاء وكلمة &quot;مافا&quot; على الجسم بحبر أسود.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كامزايوس 10 ملجم، يبلغ طولها نحو 18.0 ملم، كبسولات صلبة بغطاء وردي غير شفاف وجسم أبيض غير شفاف مع طباعة &quot;10 ملجم&quot; على الغطاء وكلمة &quot;مافا&quot; على الجسم بحبر أسود.</p><p dir="RTL">&sect;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كامزايوس 15 ملجم، يبلغ طولها نحو 18.0 ملم، كبسولات صلبة بغطاء رمادي غير شفاف وجسم أبيض غير شفاف مع طباعة &quot;15 ملجم&quot; على الغطاء وكلمة &quot;مافا&quot; على الجسم بحبر أسود.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الكبسولات الصلبة مُعبأة في شريط من رقائق الألومنيوم يحتوي على 14 كبسولة صلبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحتوي كل عبوة على 28 كبسولة صلبة. قد لا تُسوق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>حامل ترخيص التسويق</strong></p><p dir="RTL">بريستول-مايرز سكويب للأدوية (EEIG)</p><p dir="RTL">بلازا 254</p><p dir="RTL">بلانكاردستاون كوربوريت بارك 2</p><p dir="RTL">دبلن 15، D15 T867</p><p dir="RTL">أيرلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجهة المُصنعة</p><p dir="RTL">شركة باثيون المتحدة</p><p dir="RTL">2100 سينتيكس كورت</p><p dir="RTL">ميسيسوجا، أونتاريو</p><p dir="RTL">L5N 7K9، كندا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            روجعت هذه النشرة آخر مرة في اغسطس 2024.
تمت الموافقة على هذه النشرة من قبل الهيئة العامة للغذاء والدواء في 5 مايو 2025م.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CAMZYOS®
(mavacamten)

2.5 mg hard capsules
5 mg hard capsules
10 mg hard capsules
15 mg hard capsules

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CAMZYOS 2.5 mg hard capsules
Each hard capsule contains 2.5 mg of mavacamten.

CAMZYOS 5 mg hard capsules
Each hard capsule contains 5 mg of mavacamten.

CAMZYOS 10 mg hard capsules
Each hard capsule contains 10 mg of mavacamten.

CAMZYOS 15 mg hard capsules
Each hard capsule contains 15 mg of mavacamten.

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hard capsule (capsule)

CAMZYOS 2.5 mg hard capsules
Light purple opaque cap imprinted with “2.5 mg” in black, and white opaque body imprinted with “Mava” in black, both in radial direction. Capsule size of approximately 18.0 mm in length.

CAMZYOS 5 mg hard capsules
Yellow opaque cap imprinted with “5 mg” in black, and white opaque body imprinted with “Mava” in black, both in radial direction. Capsule size of approximately 18.0 mm in length.

CAMZYOS 10 mg hard capsules
Pink opaque cap imprinted with “10 mg” in black, and white opaque body imprinted with “Mava” in black, both in radial direction. Capsule size of approximately 18.0 mm in length.

CAMZYOS 15 mg hard capsules
Grey opaque cap imprinted with “15 mg” in black, and white opaque body imprinted with “Mava” in black, both in radial direction. Capsule size of approximately 18.0 mm in length.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CAMZYOS is indicated for the treatment of&nbsp;symptomatic (New York Heart Association, NYHA, class&nbsp;II‑III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated under the supervision of a physician experienced in the management of patients with cardiomyopathy.</p><p>&nbsp;</p><p>Before treatment initiation, patients&rsquo; left ventricular ejection fraction (LVEF) should be assessed by echocardiography (see section&nbsp;4.4). If LVEF is&nbsp;&lt;&nbsp;55%, treatment should not be initiated.</p><p>&nbsp;</p><p>Before initiation of treatment, women of childbearing potential must have a negative pregnancy test (see section&nbsp;4.4 and 4.6).</p><p>&nbsp;</p><p>Patients should be genotyped for Cytochrome P450 (CYP) 2C19 (CYP2C19) in order to determine appropriate mavacamten dose. Patients with CYP2C19 poor metabolizer phenotype may have increased mavacamten exposures (up to 3&nbsp;times) that can lead to increased risk of systolic dysfunction compared to normal metabolizers (see section&nbsp;4.4 and 5.2). If treatment initiation occurs prior to determination of CYP2C19 phenotype, patients should follow dosing instructions for poor metabolisers (see figure&nbsp;1 and table&nbsp;1) until CYP2C19 phenotype is determined.</p><p>&nbsp;</p><p><u>Posology</u></p><p>The dose range is 2.5&nbsp;mg to 15&nbsp;mg (either 2.5&nbsp;mg, 5&nbsp;mg, 10&nbsp;mg or 15&nbsp;mg). The bioequivalence between strengths has not been confirmed in a bioequivalence study in humans; therefore, the use of multiple capsules to achieve a prescribed dose is prohibited and one capsule of the appropriate dose strength should be used.</p><p>&nbsp;</p><p><u>CYP2C19 poor metaboliser phenotype</u></p><p>The recommended starting dose is 2.5&nbsp;mg orally once daily. The maximum dose is 5&nbsp;mg once daily. The patient should be assessed for early clinical response by left ventricular outflow tract (LVOT) gradient with Valsalva manoeuvre 4&nbsp;and 8&nbsp;weeks after treatment initiation (see figure&nbsp;1).</p><p>&nbsp;</p><p><u>CYP2C19 intermediate, normal, rapid and ultra‑rapid metaboliser phenotype</u></p><p>The recommended starting dose is 5&nbsp;mg orally once daily. The maximum dose is 15&nbsp;mg once daily. The patient should be assessed for early clinical response by LVOT gradient with Valsalva manoeuvre 4&nbsp;and 8&nbsp;weeks after treatment initiation (see figure&nbsp;2).</p><p>&nbsp;</p><p>Once an individualised maintenance dose is achieved, patients should be assessed every 12&nbsp;weeks (see figure&nbsp;3). If at any visit the patient&rsquo;s LVEF is&nbsp;&lt;&nbsp;50%, the treatment should be interrupted for 4&nbsp;weeks and until LVEF returns to&nbsp;&ge;&nbsp;50% (see figure&nbsp;4).</p><p>&nbsp;</p><p>In patients experiencing an intercurrent illness such as serious infection or arrhythmia (including atrial fibrillation or other uncontrolled tachyarrhythmia) which may impair systolic function, LVEF assessment is recommended, and dose increases are not recommended until intercurrent illness is resolved (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Consideration should be given to discontinue treatment in patients who have shown no response (e.g., no improvement in symptoms, quality of life, exercise capacity, LVOT gradient) after 4‑6&nbsp;months on the maximum tolerated dose.</p><p><img alt="" width="687" height="471" src="data:image/png;base64,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" /></p><p>* Interrupt treatment if LVEF is&nbsp;&lt;&nbsp;50% at any clinical visit; restart treatment after 4&nbsp;weeks if LVEF&nbsp;&ge;&nbsp;50% (see figure&nbsp;4).</p><p>LVEF&nbsp;=&nbsp;left ventricular ejection fraction; LVOT&nbsp;=&nbsp;left ventricular outflow tract</p><p>&nbsp;</p><p><img alt="" width="682" height="495" src="data:image/png;base64,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" /></p><p>* Interrupt treatment if LVEF is&nbsp;&lt;&nbsp;50% at any clinical visit; restart treatment after 4&nbsp;weeks if LVEF&nbsp;&ge;&nbsp;50% (see figure&nbsp;4).</p><p>LVEF&nbsp;=&nbsp;left ventricular ejection fraction; LVOT&nbsp;=&nbsp;left ventricular outflow tract</p><p><img alt="" width="682" height="479" src="data:image/png;base64,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" /></p><p>LVEF&nbsp;=&nbsp;left ventricular ejection fraction; LVOT&nbsp;=&nbsp;left ventricular outflow tract</p><p><img alt="" width="686" height="341" src="data:image/png;base64,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" /></p><p>LVEF&nbsp;=&nbsp;left ventricular ejection fraction; LVOT&nbsp;=&nbsp;left ventricular outflow tract</p><p>&nbsp;</p><p><u>Dose modification with concomitant medicinal products</u></p><p>For concomitant treatment with inhibitors and inducers of CYP2C19 or CYP3A4, follow the steps shown in table&nbsp;1 (see also section&nbsp;4.5).</p><p><strong>Table&nbsp;1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose modification of mavacamten with concomitant medicinal products</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td style="vertical-align:top"><p><strong>Concomitant medicinal product</strong></p></td><td style="vertical-align:top"><p><strong>CYP2C19 poor metaboliser phenotype*</strong></p></td><td style="vertical-align:top"><p><strong>CYP2C19 intermediate, normal, rapid and ultra‑rapid phenotype</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p style="text-align:center"><strong>Inhibitors</strong></p></td></tr><tr><td style="vertical-align:top"><p>Combined use of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor</p></td><td style="vertical-align:top"><p>Contra-indicated (see section&nbsp;4.3).</p></td><td style="vertical-align:top"><p>Contra-indicated (see section&nbsp;4.3).</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP2C19 inhibitor</p></td><td style="vertical-align:top"><p>No dose adjustment (see section&nbsp;4.5).</p><p>&nbsp;</p><p><strong>If CYP2C19 phenotype has not yet been determined:</strong></p><p>No adjustment of the starting dose of 2.5&nbsp;mg is needed.</p><p>The dose should be reduced from 5&nbsp;mg to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg (see section&nbsp;4.5).</p></td><td style="vertical-align:top"><p>Initiate mavacamten at a dose of 2.5&nbsp;mg.</p><p>&nbsp;</p><p>The dose should be reduced from 15&nbsp;mg to 5&nbsp;mg and from 10&nbsp;mg and 5&nbsp;mg to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg (see section&nbsp;4.5).</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP3A4 inhibitor</p></td><td style="vertical-align:top"><p>Contra-indicated (see section&nbsp;4.3).</p></td><td style="vertical-align:top"><p>No dose adjustment (see section&nbsp;4.5).</p></td></tr><tr><td style="vertical-align:top"><p>Moderate CYP2C19 inhibitor</p></td><td style="vertical-align:top"><p>No dose adjustment.</p><p>&nbsp;</p><p><strong>If CYP2C19 phenotype has not yet been determined:</strong></p><p>No adjustment of the starting dose of 2.5&nbsp;mg is needed.</p><p>The dose should be reduced from 5&nbsp;mg to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg (see section&nbsp;4.5).</p></td><td style="vertical-align:top"><p>No adjustment of the starting dose of 5&nbsp;mg is needed.</p><p>The dose should be reduced by one dose level or pause treatment if on 2.5&nbsp;mg (see section&nbsp;4.5).</p></td></tr><tr><td style="vertical-align:top"><p>Moderate or weak CYP3A4 inhibitor</p></td><td style="vertical-align:top"><p>No adjustment of the starting dose of 2.5&nbsp;mg is needed. If patients are receiving a 5&nbsp;mg dose of mavacamten, their dose should be reduced to 2.5&nbsp;mg (see section&nbsp;4.5).</p></td><td style="vertical-align:top"><p>No dose adjustment (see section&nbsp;4.5).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p style="text-align:center"><strong>Inducers</strong></p></td></tr><tr><td style="vertical-align:top"><p>Discontinuing or decreasing the dose of strong CYP2C19 inducer and strong CYP3A4 inducer</p></td><td style="vertical-align:top"><p>The dose should be reduced from 5&nbsp;mg to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg (see section&nbsp;4.5).</p></td><td style="vertical-align:top"><p>The dose should be reduced by one dose level when on doses 5&nbsp;mg or higher when discontinuing or decreasing the dose of strong inducers while on mavacamten (see section&nbsp;4.5).</p><p>No dose adjustment when on 2.5&nbsp;mg.</p></td></tr><tr><td style="vertical-align:top"><p>Discontinuing or decreasing the dose of moderate or weak CYP3A4 inducer</p></td><td style="vertical-align:top"><p>Decrease mavacamten dose to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg (see section&nbsp;4.5).</p></td><td style="vertical-align:top"><p>No dose adjustment (see section&nbsp;4.5).</p></td></tr></tbody></table><p>* includes patients for whom the CYP2C19 phenotype has not yet been determined.</p><p>&nbsp;</p><p><em><u>Missed or delayed doses</u></em></p><p>If a dose is missed, it should be taken as soon as possible, and the next scheduled dose should be taken at the usual time the following day. Two doses should not be taken on the same day.</p><p>&nbsp;</p><p>Special populations</p><p><em><u>Elderly</u></em></p><p>No dose adjustment to the standard dose and titration scheme is required for patients aged 65&nbsp;years and older (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>No dose adjustment to the standard dose and titration scheme is required for patients with mild (estimated glomerular filtration rate [eGFR] 60‑89&nbsp;mL/min/1.73m<sup>2</sup>) to moderate (eGFR&nbsp;30‑59&nbsp;mL/min/1.73m<sup>2</sup>) renal impairment. No dose recommendation can be made for patients with severe (eGFR &lt;&nbsp;30&nbsp;mL/min/1.73m<sup>2</sup>) renal impairment because mavacamten has not been studied in patients with severe renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>The mavacamten starting dose should be 2.5&nbsp;mg in all patients with mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic impairment since mavacamten exposure is likely to be increased (see section&nbsp;5.2). No dose recommendation can be made for patients with severe hepatic impairment (Child-Pugh class&nbsp;C) because mavacamten has not been studied in patients with severe hepatic impairment (see section&nbsp;4.4 and&nbsp;5.2).</p><p><em><u>&nbsp;</u></em></p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of mavacamten in children and adolescents below 18&nbsp;years have not been established. No data are available.</p><p>Mavacamten should not be used in children less than 12&nbsp;years because of potential safety concerns.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For oral use.</p><p>&nbsp;</p><p>Treatment should be taken once daily with or without meals at about the same time each day. Use a single capsule for a prescribed dose. The capsule should be swallowed whole with water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
	During pregnancy and in women of childbearing potential not using effective contraception (see sections 4.4 and 4.6).
	Concomitant treatment with strong CYP3A4 inhibitors in patients with CYP2C19 poor metaboliser phenotype and undetermined CYP2C19 phenotype (see sections 4.2, 4.4 and 4.5).
	Concomitant treatment with the combination of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor (see section 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Systolic dysfunction defined as symptomatic LVEF&nbsp;&lt;&nbsp;50%</u></p><p>Mavacamten reduces LVEF and may cause heart failure due to systolic dysfunction defined as symptomatic LVEF&nbsp;&lt;&nbsp;50%. Patients with a serious intercurrent illness such as infection or arrhythmia (including atrial fibrillation or other uncontrolled tachyarrhythmia), or those undergoing major cardiac surgery may be at greater risk of systolic dysfunction and progress to heart failure (see section&nbsp;4.8). New or worsening dyspnoea, chest pain, fatigue, palpitations, leg oedema or elevations in N-terminal pro‑B‑type natriuretic peptide (NT‑proBNP) may be signs and symptoms of systolic dysfunction and should prompt an evaluation of cardiac function. LVEF should be measured prior to initiating treatment and closely monitored thereafter. Treatment interruption may be necessary to ensure that LVEF remains &ge;&nbsp;50% (see section&nbsp;4.2).</p><p>&nbsp;</p><p><u>Heart failure risk or loss of response to mavacamten due to interactions</u></p><p>Mavacamten is primarily metabolised by CYP2C19 and to a lesser extent by CYP3A4 and mostly by CYP3A4 in CYP2C19 poor metabolisers, which may lead to the following interactions (see section&nbsp;4.5):</p><p>&sect;&nbsp;&nbsp;&nbsp; Starting or increasing the dose of a strong or moderate CYP3A4 inhibitor or any CYP2C19 inhibitor may increase risk of heart failure due to systolic dysfunction.</p><p>&sect;&nbsp;&nbsp;&nbsp; Stopping or decreasing dose of any inhibitor of CYP3A4 or CYP2C19 may lead to a loss of therapeutic response to mavacamten.</p><p>&sect;&nbsp;&nbsp;&nbsp; Starting a strong CYP3A4 or strong CYP2C19 inducer may lead to a loss of therapeutic response to mavacamten.</p><p>&sect;&nbsp;&nbsp;&nbsp; Stopping a strong CYP3A4 or strong CYP2C19 inducer may increase risk of heart failure due to systolic dysfunction.</p><p>&nbsp;</p><p>Prior to and during mavacamten treatment, the potential for interactions, including over the counter medicinal products (such as omeprazole or esomeprazole), should be considered.</p><p>&sect;&nbsp;&nbsp;&nbsp; Concomitant treatment with strong CYP3A4 inhibitors in patients with CYP2C19 poor metaboliser phenotype and undetermined CYP2C19 phenotype is contraindicated (see section&nbsp;4.3).</p><p>&sect;&nbsp;&nbsp;&nbsp; Concomitant treatment with the combination of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor is contraindicated (see section&nbsp;4.3).</p><p>&sect;&nbsp;&nbsp;&nbsp; Dose adjustment of mavacamten and/or close monitoring may be required in patients initiating or discontinuing treatment with, or changing the dose of concomitant medicinal products that are inhibitors or inducers of CYP2C19 or CYP3A4 (see sections&nbsp;4.2 and 4.5). Intermittent administration of these medicinal products is not recommended (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Concomitant use of negative inotropes</u></p><p>The safety of concomitant use of mavacamten with disopyramide, or use of mavacamten in patients taking beta blockers in combination with verapamil or diltiazem has not been established. Therefore, patients should be closely monitored when taking these concomitant medicinal products (see section&nbsp;4.5).</p><p><u>&nbsp;</u></p><p><u>Embryo-foetal toxicity</u></p><p>Based on animal studies, mavacamten is suspected to cause embryo-foetal toxicity when administered to a pregnant woman (see section&nbsp;5.3). Due to risk to the foetus, CAMZYOS is contraindicated during pregnancy and in women of childbearing potential not using effective contraception. Before initiation of treatment, women of childbearing potential must be informed of this risk to the foetus, must have a negative pregnancy test and must use effective contraception during treatment and for 6&nbsp;months after treatment discontinuation (see sections&nbsp;4.3 and 4.6).</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per capsule, that is to say essentially &#39;sodium-free&#39;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacodynamic interactions</u></p><p>If treatment with a new negative inotrope is initiated or if the dose of a negative inotrope is increased in a patient receiving mavacamten, close medical supervision with monitoring of LVEF should be provided until stable doses and clinical response have been achieved (see section&nbsp;4.2 and 4.4).</p><p>&nbsp;</p><p><u>Pharmacokinetic interactions</u></p><p><em><u>Effect of other medicinal products on mavacamten</u></em></p><p>In CYP2C19 intermediate, normal, rapid and ultra‑rapid metabolisers, mavacamten is primarily metabolised by CYP2C19 and to a lesser extent by CYP3A4. In CYP2C19 poor metabolisers, metabolism is mostly by CYP3A4 (see section&nbsp;5.2). CYP2C19 inhibitors/inducers and CYP3A4 inhibitors/inducers may thus affect the clearance of mavacamten and increase/decrease mavacamten plasma concentration, and this will depend on the CYP2C19 phenotype.</p><p>All clinical drug-drug interaction studies mainly enrolled CYP2C19 normal metabolisers and no CYP2C19 poor metabolisers were included in the assessment of the drug‑drug interaction and therefore the effect of co‑administration of CYP2C19 and CYP3A4 inhibitors with mavacamten in CYP2C19 poor metabolisers is not completely certain.</p><p>Recommendations for dose modification and/or additional monitoring of patients initiating or discontinuing treatment with, or changing the dose of, concomitant medicinal products that are inhibitors of CYP2C19 or CYP3A4 or inducers of CYP2C19 or CYP3A4 are provided in table&nbsp;2.</p><p>&nbsp;</p><p>Strong CYP2C19 plus strong CYP3A4 inhibitors</p><p>Co‑administration of mavacamten with the combination of a strong CYP2C19 and a strong CYP3A4 inhibitor is contra‑indicated (see section&nbsp;4.3).</p><p>&nbsp;</p><p>CYP2C19 inhibitors</p><p>The effect of a moderate and strong CYP2C19 inhibitor on the PK of mavacamten was not investigated in a clinical drug‑drug interaction study. The effect of a strong CYP2C19 inhibitor (e.g., ticlopidine) will be similar to the effect of the CYP2C19 poor metabolising status (see table&nbsp;1).</p><p>Co‑administration of mavacamten with a weak CYP2C19 inhibitor (omeprazole) resulted in a 48% increase in mavacamten AUC<sub>inf</sub> with no effect on C<sub>max</sub> in CYP2C19 normal metabolisers.</p><p>Intermittent administration of a CYP2C19 inhibitor (such as omeprazole or esomeprazole) is not recommended (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>CYP3A4 inhibitors</em></p><p>Co‑administration of mavacamten with a strong CYP3A4 inhibitor (itraconazole) in CYP2C19 normal metabolisers resulted in an increase in mavacamten plasma concentration of up to 59% and 40% in AUC<sub>0‑24</sub> and C<sub>max</sub>, respectively.</p><p>Co‑administration of mavacamten with a moderate CYP3A4 inhibitor (verapamil) in CYP2C19 normal metabolisers resulted in an increase in mavacamten plasma concentration of 16% and 52% in AUC<sub>inf</sub> and C<sub>max</sub>, respectively. This change was not considered clinically significant.</p><p>&nbsp;</p><p><em>CYP2C19 and CYP3A4 inducers</em></p><p>No clinical interaction studies were conducted to investigate the effect of concomitant administration with a strong CYP3A4 and CYP2C19 inducer. Co‑administration of mavacamten with a strong inducer of both CYP2C19 and CYP3A4 (e.g., rifampicin) is expected to significantly affect the pharmacokinetics (PK) of mavacamten and leads to reduced efficacy and therefore co‑administration with strong inducers of both CYP2C19 and CYP3A4 is not recommended. If discontinuing concomitant treatment with a strong inducer of CYP2C19 or CYP3A4 increase clinical assessments and mavacamten dose should be reduced (see section&nbsp;4.2).</p><p><strong>Table&nbsp;2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose modification/monitoring of mavacamten with concomitant medicinal products</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><thead><tr><td style="vertical-align:top"><p><strong>Concomitant medicinal product</strong></p></td><td style="vertical-align:top"><p><strong>CYP2C19 poor metaboliser phenotype*</strong></p></td><td style="vertical-align:top"><p><strong>CYP2C19 intermediate, normal, rapid and ultra‑rapid metaboliser phenotype</strong></p></td></tr></thead><tbody><tr><td colspan="3" style="vertical-align:top"><p style="text-align:center"><strong>Inhibitors</strong></p></td></tr><tr><td style="vertical-align:top"><p>Combined use of a strong CYP2C19 inhibitor and a strong CYP3A4 inhibitor</p></td><td style="vertical-align:top"><p>Contra‑indicated (see section&nbsp;4.3)</p></td><td style="vertical-align:top"><p>Contra‑indicated (see section&nbsp;4.3)</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP2C19 inhibitor (e.g., ticlopidine, fluconazole, fluvoxamine)</p></td><td style="vertical-align:top"><p>No dose adjustment. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p><p>&nbsp;</p><p><strong>If CYP2C19 phenotype has not yet been determined:</strong></p><p>No adjustment of the starting dose of 2.5&nbsp;mg is needed.</p><p>The dose should be reduced from 5&nbsp;mg to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg.</p><p>Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td><td style="vertical-align:top"><p>Initiate mavacamten at a dose of 2.5&nbsp;mg.</p><p>The dose should be reduced from 15&nbsp;mg to 5&nbsp;mg and from 10&nbsp;mg and 5&nbsp;mg to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg.</p><p>Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP3A4 inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, voriconazole, ritonavir, cobicistat, ceritinib, idelalisib, tucatinib)</p></td><td style="vertical-align:top"><p>Contra‑indicated (see section&nbsp;4.3)</p></td><td style="vertical-align:top"><p>No dose adjustment. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Moderate CYP2C19 inhibitor (e.g., fluconazole, fluoxetine, omeprazole<sup>a</sup>)</p></td><td style="vertical-align:top"><p>No dose adjustment. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section&nbsp;4.2).</p><p>&nbsp;</p><p><strong>If CYP2C19 phenotype has not yet been determined:</strong></p><p>No adjustment of the starting dose of 2.5&nbsp;mg is needed.</p><p>The dose should be reduced from 5&nbsp;mg to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section&nbsp;4.2).</p></td><td style="vertical-align:top"><p>No adjustment of the starting dose of 5&nbsp;mg is needed.</p><p>Initiating or increasing the dose of a moderate inhibitor while on mavacamten treatment:</p><p>Dose should be reduced by one dose level or pause treatment if on 2.5&nbsp;mg. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Moderate CYP3A4 inhibitor (e.g., erythromycin, grapefruit juice, verapamil, diltiazem)</p></td><td style="vertical-align:top"><p>If on medication when starting mavacamten, no adjustment of the starting dose of 2.5&nbsp;mg is needed.</p><p><em>&nbsp;</em></p><p>Initiating or increasing the dose of a moderate inhibitor while on mavacamten treatment:</p><p>If patients are receiving a 5&nbsp;mg dose of mavacamten, their dose should be reduced to 2.5&nbsp;mg or if on 2.5&nbsp;mg pause treatment for 4&nbsp;weeks.</p><p>Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td><td style="vertical-align:top"><p>No dose adjustment. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Weak CYP2C19 inhibitor (e.g., cimetidine, citalopram, omeprazole<sup>a</sup>, esomeprazole)</p></td><td style="vertical-align:top"><p>No dose adjustment. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section&nbsp;4.2).</p></td><td style="vertical-align:top"><p>Initiating or increasing the dose of a weak inhibitor while on mavacamten treatment:</p><p>Monitor LVEF 4&nbsp;weeks later, and subsequently resume the patient&rsquo;s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Weak CYP3A4 inhibitor (e.g., cimetidine, esomeprazole, omeprazole, pantoprazole)</p></td><td style="vertical-align:top"><p>If on medication when starting mavacamten, no adjustment of the starting dose of 2.5&nbsp;mg is needed.</p><p>&nbsp;</p><p>Initiating or increasing the dose of weak inhibitor while on mavacamten treatment:</p><p>If patients are receiving a 5&nbsp;mg dose of mavacamten, their dose should be reduced to 2.5&nbsp;mg or if on 2.5&nbsp;mg pause treatment for 4&nbsp;weeks.</p><p>Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td><td style="vertical-align:top"><p>Initiating or increasing the dose of a weak inhibitor while on mavacamten treatment:</p><p>No dose adjustment. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section&nbsp;4.2).</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p style="text-align:center"><strong>Inducers</strong></p></td></tr><tr><td style="vertical-align:top"><p>Strong CYP2C19 inducer and strong CYP3A4 inducer (e.g., rifampicin, apalutamide, enzalutamide, mitotane, phenytoin, carbamazepine, efavirenz, St. John&rsquo;s wort)</p></td><td style="vertical-align:top"><p>Initiating or increasing the dose of strong inducer while on mavacamten treatment:</p><p>Monitor LVOT gradient and LVEF 4&nbsp;weeks later. Adjust mavacamten dose based on clinical assessment and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2). The maximum dose is 5&nbsp;mg.</p><p>&nbsp;</p><p>Discontinuing or decreasing the dose of strong inducer while on mavacamten treatment:</p><p>Decrease mavacamten dose from 5&nbsp;mg to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td><td style="vertical-align:top"><p>Initiating or increasing the dose of strong inducer while on mavacamten treatment:</p><p>Monitor LVOT gradient and LVEF 4&nbsp;weeks later. Adjust mavacamten dose based on clinical assessment and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p><p><em>&nbsp;</em></p><p>Discontinuing or decreasing the dose of strong inducer while on mavacamten treatment:</p><p>Decrease mavacamten by one dose level when on doses 5&nbsp;mg or higher. Maintain mavacamten dose when on 2.5&nbsp;mg. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Moderate or weak CYP2C19 inducer (e.g., letermovir, norethindrone, prednisone)</p></td><td style="vertical-align:top"><p>No dose adjustment. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section&nbsp;4.2).</p></td><td style="vertical-align:top"><p>Initiating the dose of moderate or weak inducer while on mavacamten treatment:</p><p>Monitor LVOT gradient and LVEF 4&nbsp;weeks later. Adjust mavacamten dose based on clinical assessment and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Discontinuing a moderate or weak inducer while on mavacamten treatment:</p><p>Decrease mavacamten by one dose level when on doses 5&nbsp;mg or higher. Maintain mavacamten dose when on 2.5&nbsp;mg.</p><p>Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section&nbsp;4.2).</p></td></tr><tr><td style="vertical-align:top"><p>Moderate or weak CYP3A4 inducer (e.g., phenobarbital, primidone)</p></td><td style="vertical-align:top"><p>Initiating or increasing the dose of moderate or weak inducer while on mavacamten treatment:</p><p>Monitor LVOT gradient and LVEF 4&nbsp;weeks later. Adjust mavacamten dose based on clinical assessment and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p><p>&nbsp;</p><p>Discontinuing or decreasing the dose of moderate or weak inducer while on mavacamten treatment:</p><p>Decrease mavacamten dose to 2.5&nbsp;mg or pause treatment if on 2.5&nbsp;mg. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule (see section&nbsp;4.2).</p></td><td style="vertical-align:top"><p>No dose adjustment. Monitor LVEF 4&nbsp;weeks later, and then resume the patient&rsquo;s monitoring and titration schedule. Adjust mavacamten dose based on clinical assessment (see section&nbsp;4.2).</p></td></tr></tbody></table><p>* Includes patients for whom the CYP2C19 phenotype has not yet been determined.</p><p><sup>a</sup> Omeprazole is considered a weak CYP2C19 inhibitor at a dose of 20&nbsp;mg once daily and a moderate CYP2C19 inhibitor at a total daily dose of 40&nbsp;mg.</p><p><em><u>Effect of mavacamten on </u></em><em><u>other medicinal products</u></em></p><p>Mavacamten <em>in vitro</em> data suggest a potential induction of CYP3A4. Co‑administration of a 17‑day course of mavacamten at clinical relevant exposures in CYP2C19 normal, rapid and ultra‑rapid metabolisers did not decrease the exposure to ethinyl oestradiol and norethindrone, which are the components of typical oral contraceptives and substrates for CYP3A4. Furthermore, co‑administration of a 16‑day course of mavacamten in CYP2C19 normal metabolisers, at clinical relevant exposures, resulted in a 13% decrease in midazolam plasma concentration. This change was not considered clinically significant.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in females</u></p><p>CAMZYOS is contraindicated in women of childbearing potential not using effective contraception (see section&nbsp;4.3). Therefore, before initiation of treatment in women of childbearing potential, a negative pregnancy test result must be available and counselling should be provided regarding the serious risk to the foetus. Women of childbearing potential must use effective contraception during treatment and for 6&nbsp;months after discontinuation of CAMZYOS, since it takes approximately 5&nbsp;half‑lives (approximately 45&nbsp;days for CYP2C19 normal metabolisers and 115&nbsp;days for CYP2C19 poor metabolisers) to eliminate mavacamten from the body after treatment discontinuation (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p>When stopping mavacamten therapy for planning a pregnancy the possible return of LVOT obstruction and symptom burden should be considered (see section&nbsp;4.4).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>There are no data from the use of mavacamten in pregnant women. Studies in animals have shown reproductive toxicity (see section&nbsp;5.3). Mavacamten is suspected to cause embryo-foetal toxicity when administered during pregnancy. Therefore, CAMZYOS is contraindicated during pregnancy (see section&nbsp;4.3). CAMZYOS should be stopped 6&nbsp;months before planning a pregnancy (see section&nbsp;4.4). If a patient becomes pregnant, mavacamten must be discontinued. Medical advice should be given regarding the risk of harmful effects to the foetus associated with treatment and ultrasonography examinations should be performed.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>It is unknown whether mavacamten or its metabolites are excreted in human milk. There is no information on the excretion of mavacamten or its metabolites in animal milk (see section&nbsp;5.3). Because of the unknown adverse effects of mavacamten in breastfed newborns/infants, women must not breast-feed during treatment with mavacamten.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>No human fertility data on mavacamten are available. Studies in animals are insufficient with respect to male or female fertility (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mavacamten has minor influence on the ability to drive and use machines. Dizziness may occur during use of mavacamten. Patients should be advised not to drive or use machines if they experience dizziness.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>4.8.1 Adverse reactions</strong></p><p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions with mavacamten are dizziness (17%), dyspnoea (12%), systolic dysfunction (5%) and syncope (5%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions reported in patients treated with mavacamten in two phase&nbsp;3 studies are tabulated below. A total of 179&nbsp;patients received a daily dose of either 2.5&nbsp;mg, 5&nbsp;mg, 10&nbsp;mg or 15&nbsp;mg of mavacamten. The median treatment duration for patients receiving mavacamten was 30.1&nbsp;weeks (range:&nbsp;1.6 to 40.3&nbsp;weeks).</p><p>&nbsp;</p><p>The adverse reactions included in table&nbsp;3 are listed according to system organ class in MedDRA. Within each system organ class, the adverse reactions are presented in order of decreasing frequency and seriousness. In addition, the corresponding frequency category for each adverse reaction is defined as: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10&nbsp;000 to &lt;&nbsp;1/1&nbsp;000); very rare (&lt;&nbsp;1/10&nbsp;000).</p><p><strong>Table&nbsp;3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:102%"><thead><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Adverse reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td rowspan="2"><p><strong>Nervous system disorders</strong></p></td><td><p>Dizziness</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td><p>Syncope</p></td><td style="vertical-align:top"><p>Common</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>Systolic dysfunction<sup>a</sup></p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>Very common</p></td></tr></tbody></table><p><sup>a </sup>Defined as LVEF &lt;&nbsp;50% with or without symptoms.</p><p><u>Description of selected adverse reactions</u></p><p><em><u>Systolic dysfunction</u></em></p><p>In Phase&nbsp;3 clinical studies, 5% (9/179) of patients in the mavacamten group experienced reversible reductions in LVEF &lt;&nbsp;50% (median&nbsp;45%: range:&nbsp;35‑49%) while on treatment. In 56%&nbsp;(5/9) of these patients, reductions were observed without other clinical manifestations. In all patients treated with mavacamten, LVEF recovered following interruption of mavacamten and they completed the study on treatment (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em><u>Dyspnoea</u></em></p><p>In Phase&nbsp;3 clinical studies, dyspnoea was reported in 12.3% of patients treated with mavacamten compared to 8.7% of patients on placebo. In the EXPLORER-HCM study, most (67%) of the dyspnoea events were reported after mavacamten was discontinued, with median time to onset of 2&nbsp;weeks (range:&nbsp;0.1‑4.9) after last dose.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>The National Pharmacovigilance Centre (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><thead><tr><td><p>Please contact the relevant competent authority.</p></td></tr></thead></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Human experience of overdose with mavacamten is limited. Mavacamten has been given as a single dose of up to 144&nbsp;mg in patients with HCM. There was one serious adverse reaction of vasovagal reaction, hypotension, and asystole lasting 38&nbsp;seconds reported at that dose. In healthy subjects, doses of up to 25&nbsp;mg have been administered for up to 25&nbsp;days. A reduction of LVEF by 20% or greater was experienced in 3 out of 8&nbsp;participants treated at the 25&nbsp;mg dose level. Systolic dysfunction is the most likely result of overdose of mavacamten. If warranted, treatment of overdose with mavacamten consists of discontinuation of mavacamten treatment as well as medically supportive measures to maintain hemodynamic status (e.g. initiation of inotropic support with adrenergic agents), including close monitoring of vital signs and LVEF and management of the clinical status of the patient.</p><p>&nbsp;</p><p>In healthy subjects fasted overnight, administration of activated charcoal 2&nbsp;hours (approximately t<sub>max</sub>) after ingestion of a 15&nbsp;mg dose of mavacamten reduced absorption as expressed by AUC<sub>0‑72</sub> by 20%. Administration of activated charcoal 6&nbsp;hours after the mavacamten dose had no effect on the absorption. Thus, early administration (prior to or as soon after t<sub>max</sub> as possible) of activated charcoal may be considered in the management of mavacamten overdose or accidental ingestion. Under fed conditions, activated charcoal may still be effective beyond 2‑hour post mavacamten dose because of the delayed t<sub>max</sub> (see section&nbsp;5.2).</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Cardiac therapy, Other cardiac preparations, ATC code: C01EB24</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Mavacamten is a selective, allosteric, and reversible cardiac myosin inhibitor. Mavacamten modulates the number of myosin heads that can enter power-generating states, thus reducing (or in HCM normalizing) the probability of force-producing systolic and residual diastolic cross-bridge formation. Mavacamten also shifts the overall myosin population towards an energy-sparing, but recruitable, super-relaxed state. Excess cross-bridge formation and dysregulation of the super-relaxed state of myosin are mechanistic hallmarks of HCM, which can result in hyper-contractility, impaired relaxation, excess energy consumption, and myocardial wall stress. In HCM patients, cardiac myosin inhibition with mavacamten normalises contractility, reduces dynamic LVOT obstruction, and improves cardiac filling pressures.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em><u>LVEF</u></em></p><p>In the EXPLORER-HCM study, mean (SD) resting LVEF was 74%&nbsp;(6) at baseline in both treatment arms, reductions in mean absolute change from baseline in LVEF was ‑4% (95%&nbsp;CI: ‑5.3, ‑2.5) in the mavacamten arm and 0% (95%&nbsp;CI: ‑1.2, 1.0) in the placebo arm over the 30‑week treatment period. At Week&nbsp;38, following an 8‑week interruption of mavacamten, mean LVEF was similar to baseline for both treatment arms.</p><p>&nbsp;</p><p><em><u>LVOT obstruction</u></em></p><p>In the EXPLORER-HCM study, patients achieved reductions in mean resting and provoked (Valsalva) LVOT&nbsp;gradient by week&nbsp;4 which were sustained throughout the 30‑week study duration. At week&nbsp;30, the mean change from baseline in resting and Valsalva LVOT gradients were ‑39&nbsp;(95%&nbsp;CI: ‑44.0, ‑33.2)&nbsp;mmHg and ‑49&nbsp;(95%&nbsp;CI: ‑55.4, ‑43.0)&nbsp;mmHg, respectively, for mavacamten arm and ‑6&nbsp;(95%&nbsp;CI: ‑10.5, ‑0.5)&nbsp;mmHg and ‑12&nbsp;(95%&nbsp;CI: ‑17.6, ‑6.6)&nbsp;mmHg, respectively, for the placebo arm. At week&nbsp;38, following 8&nbsp;weeks of mavacamten washout, mean LVEF and LVOT&nbsp;gradients were similar to baseline for both treatment arms.</p><p>&nbsp;</p><p><em><u>Cardiac electrophysiology</u></em></p><p>In HCM, the QT interval may be intrinsically prolonged due to the underlying disease, in association with ventricular pacing, or in association with medicinal products with potential for QT prolongation commonly used in the HCM population. An exposure-response analysis across all clinical studies in HCM patients has shown a concentration-dependent shortening of the QTcF interval with mavacamten. The mean placebo corrected change from baseline in oHCM patients was ‑8.7&nbsp;ms (upper and lower limit of the 90%&nbsp;CI&nbsp;‑6.7&nbsp;ms and ‑10.8&nbsp;ms, respectively) at the median steady-state C<sub>max</sub> of 452&nbsp;ng/mL. Patients with longer baseline QTcF intervals tended to display the greatest shortening.</p><p>&nbsp;</p><p>Consistent with nonclinical findings in normal hearts, in one clinical study in healthy subjects sustained exposure to mavacamten at supratherapeutic levels leading to marked depression of systolic function was associated with QTc prolongation (&lt;&nbsp;20&nbsp;ms). No acute QTc changes have been observed at comparable (or higher) exposures after single doses. The findings in healthy hearts are attributed to an adaptive response to the cardiac mechanical/functional changes (marked mechanical LV depression) occurring in response to myosin inhibition in hearts with normal physiology and LV contractility.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p><u>EXPLORER-HCM</u></p><p>The efficacy of mavacamten was evaluated in a double-blind, randomised, placebo-controlled, parallel-arm, multicentre, international, Phase&nbsp;3 study enrolling 251&nbsp;adult patients with NYHA class II and III oHCM, LVEF&nbsp;&ge;&nbsp;55%, and LVOT peak gradient &ge;&nbsp;50&nbsp;mmHg at rest or with provocation at time of oHCM diagnosis and Valsalva LVOT gradient &ge;&nbsp;30&nbsp;mmHg at screening. The majority of patients received background HCM treatment for a total of 96% in mavacamten arm (beta blockers 76%, calcium channel blockers 20%) and of 87% in the placebo arm (beta blockers 74%, calcium channel blockers 13%).</p><p>&nbsp;</p><p>Patients were randomised in a 1:1 ratio to receive either a starting dose of 5&nbsp;mg of mavacamten (123&nbsp;patients) or matching placebo (128&nbsp;patients) once daily for 30&nbsp;weeks. The dose was periodically adjusted to optimise patients&rsquo; response (decrease in LVOT&nbsp;gradient with Valsalva manoeuvre), maintain LVEF&nbsp;&ge;&nbsp;50%, and was also guided by plasma concentrations of mavacamten. Within the dose range of 2.5&nbsp;mg to 15&nbsp;mg, a total of 60&nbsp;patients received 5&nbsp;mg and 40&nbsp;patients received 10&nbsp;mg. During the study, 3 of 7&nbsp;patients on mavacamten had LVEF &lt;&nbsp;50% prior to the week&nbsp;30 visit and temporarily interrupted their dose; 2&nbsp;patients resumed treatment at the same dose and 1&nbsp;patient had the dose reduced from 10&nbsp;mg to 5&nbsp;mg.</p><p>&nbsp;</p><p>Treatment assignment was stratified by baseline NYHA class (II or III), current treatment with beta blockers (yes or no), and type of ergometer (treadmill or exercise bicycle) used for assessment of peak oxygen consumption (pVO<sub>2</sub>). Patients on background dual treatment with beta blocker and calcium channel blocker treatment or disopyramide or ranolazine were excluded. Patients with known infiltrative or storage disorder causing cardiac hypertrophy that mimicked oHCM, such as Fabry disease, amyloidosis, or Noonan syndrome with LV hypertrophy, were also excluded.</p><p>&nbsp;</p><p>The baseline demographic and disease characteristics were balanced between mavacamten and placebo. The mean age was 59&nbsp;years, 54% (mavacamten) <em>vs</em> 65% (placebo) were male, mean body mass index (BMI) was 30&nbsp;kg/m<sup>2</sup>, mean heart rate 63&nbsp;bpm, mean blood pressure 128/76&nbsp;mmHg, and 90% were Caucasian. At baseline, approximately 73% of randomised subjects were NYHA class&nbsp;II and 27% were NYHA class&nbsp;III. The mean LVEF was 74%, and the mean Valsalva LVOT was 73&nbsp;mmHg. 8% had prior septal reduction therapy, 75% were on beta -blockers, 17% were on calcium channel blockers, 14% had history of atrial fibrillation, and 23% with implantable cardioverter defibrillator (23%). In EXPLORER-HCM there were 85&nbsp;patients aged 65&nbsp;years or older, 45&nbsp;patients were dosed with mavacamten.</p><p>&nbsp;</p><p>The primary outcome measure included a change at week&nbsp;30 in exercise capacity measured by pVO<sub>2 </sub>and symptoms measured by NYHA functional classification, defined as an improvement of pVO<sub>2</sub> by &ge;&nbsp;1.5&nbsp;mL/kg/min and an improvement in NYHA class by at least 1 OR an improvement of pVO<sub>2</sub> by&nbsp;&ge;&nbsp;3.0&nbsp;mL/kg/min and no worsening in NYHA class.</p><p>&nbsp;</p><p>A greater proportion of patients treated with mavacamten met the primary and secondary endpoints at week&nbsp;30 compared to placebo (see table&nbsp;4).</p><p><strong>Table&nbsp;4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Analysis of the primary composite and secondary endpoints from EXPLORER‑HCM study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:618px"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mavacamten</strong></p><p><strong>N&nbsp;=&nbsp;123</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N&nbsp;=&nbsp;128</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Patients achieving primary endpoint at week&nbsp;30, n (%)</strong></p></td><td><p>45 (37%)</p></td><td colspan="2"><p>22 (17%)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference (95%&nbsp;CI)</p></td><td colspan="3"><p>19.4 (8.67, 30.13)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="3"><p>0.0005</p></td></tr><tr><td style="vertical-align:top"><p><strong>Change from baseline post-exercise LVOT peak gradient at week&nbsp;30, </strong><strong>mmHg</strong></p></td><td colspan="2"><p>N&nbsp;=&nbsp;123</p></td><td><p>N&nbsp;=&nbsp;128</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td colspan="2"><p>-47 (40)</p></td><td><p>-10 (30)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference* (95%&nbsp;CI)</p></td><td colspan="3"><p>-35 (-43, -28)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="3"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Change from baseline to week&nbsp;30 in pVO<sub>2</sub>, </strong><strong>mL/kg/min</strong></p></td><td colspan="2"><p>N&nbsp;=&nbsp;123</p></td><td><p>N&nbsp;=&nbsp;128</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td colspan="2"><p>1.4 (3)</p></td><td><p>-0.05 (3)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference* (95%&nbsp;CI)</p></td><td colspan="3"><p>1.4 (0.6, 2)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="3"><p>&lt;&nbsp;0.0006</p></td></tr><tr><td style="vertical-align:top"><p><strong>Patients with improvement of NYHA class &ge;&nbsp;1 at week&nbsp;30</strong></p></td><td colspan="2"><p>N&nbsp;=&nbsp;123</p></td><td><p>N&nbsp;=&nbsp;128</p></td></tr><tr><td style="vertical-align:top"><p>N, (%)</p></td><td colspan="2"><p>80 (65%)</p></td><td><p>40 (31%)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference (95%&nbsp;CI)</p></td><td colspan="3"><p>34 (22, 45)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="3"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Change from baseline to week&nbsp;30 in KCCQ‑23 CSS&dagger;</strong></p></td><td colspan="2"><p>N&nbsp;=&nbsp;92</p></td><td><p>N&nbsp;=&nbsp;88</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td colspan="2"><p>14 (14)</p></td><td><p>4 (14)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference* (95%&nbsp;CI)</p></td><td colspan="3"><p>9 (5, 13)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="3"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td><p><strong>Baseline</strong></p></td><td colspan="2"><p>N&nbsp;=&nbsp;99</p></td><td><p>N&nbsp;=&nbsp;97</p></td></tr><tr><td><p>Mean (SD)</p></td><td colspan="2"><p>71 (16)</p></td><td><p>71 (19)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Change from baseline to week&nbsp;30 in HCMSQ SoB domain score&Dagger;</strong></p></td><td colspan="2"><p>N&nbsp;=&nbsp;85</p></td><td><p>N&nbsp;=&nbsp;86</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td colspan="2"><p>-2.8 (2.7)</p></td><td><p>-0.9 (2.4)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference* (95%&nbsp;CI)</p></td><td colspan="3"><p>-1.8 (-2.4, -1.2)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="3"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td><p><strong>Baseline</strong></p></td><td colspan="2"><p>N&nbsp;=&nbsp;108</p></td><td><p>N&nbsp;=&nbsp;109</p></td></tr><tr><td><p>Mean (SD)</p></td><td colspan="2"><p>4.9 (2.5)</p></td><td><p>4.5 (3.2)</p></td></tr></tbody></table><p>* Least-squares mean difference</p><p>&dagger; KCCQ-23&nbsp;CSS&nbsp;=&nbsp;Kansas City Cardiomyopathy Questionnaire‑23 Clinical Summary Score. The KCCQ‑23&nbsp;CSS is derived from the Total Symptoms Score (TSS) and the Physical Limitations (PL) score of the KCCQ‑23. The CSS ranges from&nbsp;0 to&nbsp;100, with higher scores representing better health status. A significant treatment effect on the KCCQ‑23 CSS favouring mavacamten was first observed at week&nbsp;6 and remained consistent through week&nbsp;30.</p><p>&Dagger; HCMSQ SoB&nbsp;=&nbsp;Hypertrophic Cardiomyopathy Symptom Questionnaire Shortness of Breath. The HCMSQ&nbsp;SoB domain score measures frequency and severity of shortness of breath. The HCMSQ&nbsp;SoB domain score ranges from&nbsp;0 to&nbsp;18, with lower scores representing less shortness of breath. A significant treatment effect on the HCMSQ&nbsp;SoB favouring mavacamten was first observed at week&nbsp;4 and remained consistent through week&nbsp;30.</p><p>&nbsp;</p><p>A range of demographic characteristics, baseline disease characteristics, and baseline concomitant medicinal products were examined for their influence on outcomes. Results of the primary analysis consistently favoured mavacamten across all subgroups analysed.</p><p>&nbsp;</p><p><u>VALOR-HCM</u></p><p>The efficacy of mavacamten was evaluated in a Phase&nbsp;3, double-blind, randomised, 16‑week placebo‑controlled trial in 112&nbsp;patients with symptomatic oHCM who were septal reduction therapy (SRT) eligible. Patients with severely symptomatic drug-refractory oHCM, and NYHA class&nbsp;III/IV or class&nbsp;II with exertional syncope or near syncope were included in the study. Patients were required to have LVOT peak gradient &ge;&nbsp;50&nbsp;mmHg at rest or with provocation, and LVEF &ge;&nbsp;60%. Patients must have been referred or under active consideration within the past 12&nbsp;months for SRT and had been actively considering scheduling the procedure.</p><p>&nbsp;</p><p>Patients were randomised 1:1 to receive treatment with mavacamten or placebo once daily. The dose was periodically adjusted within the dose range of 2.5&nbsp;mg to 15&nbsp;mg to optimise patient&rsquo;s response.</p><p>&nbsp;</p><p>The baseline demographic and disease characteristics were balanced between mavacamten and placebo. The mean age was 60.3&nbsp;years, 51% were male, mean BMI was 31&nbsp;kg/m<sup>2</sup>, mean heart rate 64&nbsp;bpm, mean blood pressure 131/74&nbsp;mmHg, and 89% were Caucasian. At baseline, approximately 7% of randomised subjects were NYHA class&nbsp;II and 92% were NYHA class&nbsp;III. 46% were on beta‑blockers monotherapy, 15% were on calcium channel blockers monotherapy, 33% were on a mixed combination of beta -blockers, calcium channel blockers, and 20% were on disopyramide alone or in combination with other treatment. In VALOR-HCM there were 45&nbsp;patients aged 65&nbsp;years or older, 24&nbsp;patients were dosed with mavacamten.</p><p>&nbsp;</p><p>Mavacamten was shown to be superior to placebo in meeting the primary composite endpoint at week&nbsp;16 (see table&nbsp;5). The primary endpoint was a composite of</p><p>&sect;&nbsp;&nbsp;&nbsp; patient decision to proceed with SRT prior to or at week&nbsp;16 or</p><p>&sect;&nbsp;&nbsp;&nbsp; patients who remain SRT eligible (LVOT gradient of &ge;&nbsp;50&nbsp;mmHg and NYHA class&nbsp;III‑IV, or class&nbsp;II with exertional syncope or near syncope) at week&nbsp;16.</p><p>&nbsp;</p><p>The treatment effects of mavacamten on LVOT obstruction, functional capacity, health status, and cardiac biomarkers were assessed by change from baseline through week&nbsp;16 in post‑exercise LVOT gradient, proportion of patients with improvement in NYHA class, KCCQ‑23 CSS, NT‑proBNP, and cardiac troponin&nbsp;I. In the VALOR-HCM study, hierarchical testing of secondary efficacy endpoints showed significant improvement in the mavacamten group compared to the placebo group (see table&nbsp;5).</p><p><strong>Table&nbsp;5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Analysis of the primary composite and secondary endpoints from VALOR-HCM study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:614px"><thead><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Mavacamten</strong></p><p><strong>N&nbsp;=&nbsp;56</strong></p></td><td style="vertical-align:top"><p><strong>Placebo</strong></p><p><strong>N&nbsp;=&nbsp;56</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Patients achieving primary composite endpoint at week&nbsp;16, n (%)</p></td><td style="vertical-align:top"><p>10 (17.9)</p></td><td style="vertical-align:top"><p>43 (76.8)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>58.9 (44.0, 73.9)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patient decision to proceed with SRT</p></td><td style="vertical-align:top"><p>2 (3.6)</p></td><td style="vertical-align:top"><p>2 (3.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SRT-eligible based on guideline criteria</p></td><td style="vertical-align:top"><p>8 (14.3)</p></td><td style="vertical-align:top"><p>39 (69.6)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SRT status not evaluable (imputed as meeting primary endpoint)</p></td><td style="vertical-align:top"><p>0 (0.0)</p></td><td style="vertical-align:top"><p>2 (3.6)</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline post-Exercise LVOT peak gradient at week&nbsp;16, (mmHg)</p></td><td><p>N&nbsp;=&nbsp;55</p></td><td><p>N&nbsp;=&nbsp;53</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>-39.1 (36.5)</p></td><td style="vertical-align:top"><p>-1.8 (28.8)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference* (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>-37.2 (-48.1, -26.2)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Patients with improvement of NYHA class&nbsp;&ge;&nbsp;1 at week&nbsp;16</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;55</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;53</p></td></tr><tr><td style="vertical-align:top"><p>N, (%)</p></td><td style="vertical-align:top"><p>35 (62.5%)</p></td><td style="vertical-align:top"><p>12 (21.4%)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>41.1 (24.5%, 57.7%)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline to week&nbsp;16 in KCCQ-23 CSS<sup>&dagger;</sup></p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;55</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;53</p></td></tr><tr><td style="vertical-align:top"><p>Mean (SD)</p></td><td style="vertical-align:top"><p>10.4 (16.1)</p></td><td style="vertical-align:top"><p>1.8 (12.0)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment difference* (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>9.5 (4.9, 14.0)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>Baseline</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;56</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;56</p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>mean (SD)</p></td><td style="vertical-align:top"><p>69.5 (16.3)</p></td><td style="vertical-align:top"><p>65.6 (19.9)</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline to week&nbsp;16 in NT-proBNP</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;55</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;53</p></td></tr><tr><td style="vertical-align:top"><p>ng/L geometric mean ratio</p></td><td style="vertical-align:top"><p>0.35</p></td><td style="vertical-align:top"><p>1.13</p></td></tr><tr><td style="vertical-align:top"><p>Geometric mean ratio mavacamten/placebo (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.33 (0.27, 0.42)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr><tr><td style="vertical-align:top"><p>Change from baseline to week&nbsp;16 in Cardiac Troponin I</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;55</p></td><td style="vertical-align:top"><p>N&nbsp;=&nbsp;53</p></td></tr><tr><td style="vertical-align:top"><p>ng/L geometric mean ratio</p></td><td style="vertical-align:top"><p>0.50</p></td><td style="vertical-align:top"><p>1.03</p></td></tr><tr><td style="vertical-align:top"><p>Geometric mean ratio mavacamten/placebo (95%&nbsp;CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.53 (0.41, 0.70)</p></td></tr><tr><td style="vertical-align:top"><p>p‑value</p></td><td colspan="2" style="vertical-align:top"><p>&lt;&nbsp;0.0001</p></td></tr></tbody></table><p><sup>*</sup> Least-squares mean difference.</p><p><sup>&dagger;</sup> KCCQ‑23&nbsp;CSS=Kansas City Cardiomyopathy Questionnaire‑23 Clinical Summary Score. The KCCQ‑23&nbsp;CSS is derived from the Total Symptoms Score (TSS) and the Physical Limitations (PL) score of the KCCQ‑23. The CSS ranges from 0 to 100, with higher scores representing better health status.</p><p>&nbsp;</p><p>In the VALOR‑HCM study, secondary endpoint of NT-proBNP, at week&nbsp;16 (see table&nbsp;5) showed a sustained reduction from baseline after mavacamten treatment compared to placebo that was similar to that seen in EXPLORER‑HCM at week&nbsp;30.</p><p>Exploratory analysis of left ventricular mass index (LVMI) and left atrial volume index (LAVI) showed reductions in the mavacamten treated patients compared to placebo in EXPLORER-HCM and VALOR‑HCM.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with CAMZYOS in one or more subsets of the paediatric population in treatment of HCM (see section&nbsp;4.2 for information on paediatric use).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Mavacamten is readily absorbed with a median t<sub>max </sub>of 1&nbsp;hour (range: 0.5 to 3&nbsp;hours) after oral administration with an estimated oral bioavailability of approximately&nbsp;85% within the clinical dose range. The increase in mavacamten exposure is generally dose proportional after once daily doses of mavacamten (2&nbsp;mg to 48&nbsp;mg).</p><p>&nbsp;</p><p>After a single dose of 15&nbsp;mg mavacamten, C<sub>max</sub> and AUC<sub>inf</sub> are 47% and 241% higher, respectively, in CYP2C19&nbsp;poor metabolisers compared to normal metabolisers. Mean half-life is prolonged in CYP2C19&nbsp;poor metabolisers compared to normal metabolisers (23&nbsp;days <em>versus</em> 6 to&nbsp;9&nbsp;days, respectively).</p><p>&nbsp;</p><p>Inter‑subject PK variability is moderate, with a coefficient of variation for exposure of approximately&nbsp;30‑50% for C<sub>max</sub> and AUC.</p><p>&nbsp;</p><p>A high fat, high calorie meal delayed absorption resulting in a median t<sub>max</sub> of 4&nbsp;hours (range: 0.5 to 8&nbsp;hours) in the fed state compared to 1&nbsp;h in the fasted state. Administration with meals resulted in a 12% decrease in AUC<sub>0-inf</sub>, however this decrease is not considered clinically significant. Mavacamten may be administered with or without meals.</p><p>&nbsp;</p><p>As mavacamten is titrated based on clinical response (see section&nbsp;4.2), simulated steady state exposures are summarized using individualised dosage by phenotype (see table&nbsp;6).</p><p><strong>Table&nbsp;6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Simulated average steady state concentration by dose and CYP2C19 phenotype in patients titrated to effect based on Valsalva LVOT and LVEF</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:604px"><thead><tr><td style="vertical-align:top"><p>Dose</p></td><td colspan="5" style="vertical-align:top"><p>Median concentration (ng/ml)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Poor metabolisers</p></td><td style="vertical-align:top"><p>Intermediate metabolisers</p></td><td style="vertical-align:top"><p>Normal metabolisers</p></td><td style="vertical-align:top"><p>Rapid metabolisers</p></td><td style="vertical-align:top"><p>Ultra-rapid metabolisers</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>2.5&nbsp;mg</p></td><td style="vertical-align:top"><p>451.9</p></td><td style="vertical-align:top"><p>274.0</p></td><td style="vertical-align:top"><p>204.9</p></td><td style="vertical-align:top"><p>211.3</p></td><td style="vertical-align:top"><p>188.3</p></td></tr><tr><td style="vertical-align:top"><p>5&nbsp;mg</p></td><td style="vertical-align:top"><p>664.9</p></td><td style="vertical-align:top"><p>397.8</p></td><td style="vertical-align:top"><p>295.4</p></td><td style="vertical-align:top"><p>311.5</p></td><td style="vertical-align:top"><p>300.5</p></td></tr></tbody></table><p><u>Distribution</u></p><p>Plasma protein binding of mavacamten is 97‑98% in clinical studies. The blood‑to‑plasma concentration ratio is 0.79. The apparent volume of distribution (Vd/F) ranged from 114&nbsp;L to 206&nbsp;L. Specific studies to assess distribution of mavacamten have not been conducted in humans, however data are consistent with a high volume of distribution.</p><p>&nbsp;</p><p>Based upon 10&nbsp;male subjects dosed for up to 28&nbsp;days, the amount of mavacamten distributed to the semen was considered to be low.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>Mavacamten is extensively metabolised, primarily through CYP2C19 (74%), CYP3A4 (18%), and CYP2C9 (7.6%) based on in-vitro reaction phenotyping. Metabolism is expected to be driven through all three pathways, and primarily through CYP2C19 in CYP2C19 intermediate, normal, rapid and ultra‑rapid metabolisers. Three metabolites have been detected in human plasma. The exposure of the most abundant metabolite MYK‑1078 in human plasma was less than 4% of the exposure of mavacamten, and the other two metabolites had exposures less than 3% of the exposure of mavacamten indicating these would have minimal to no impact on the overall activity of mavacamten. In CYP2C19 poor metabolisers mavacamten is metabolised primarily by CYP3A4. No data are available on the metabolite profile in CYP2C19 poor metabolisers.</p><p>&nbsp;</p><p><em><u>Effect of mavacamten on other CYP enzymes</u></em></p><p>Based on pre-clinical data, for a dose up to 5&nbsp;mg in CYP2C19 poor metabolisers and for a dose up to 15&nbsp;mg in CYP2C19 intermediate to ultra‑rapid metabolisers, mavacamten is not an inhibitor of CYP 1A2, 2B6, 2C8, 2D6, 2C9, 2C19, or 3A4 at clinically relevant concentrations.</p><p>&nbsp;</p><p><em><u>Effect of mavacamten on transporters</u></em></p><p><em>In vitro</em> data indicate that mavacamten is not an inhibitor of major efflux transporters (P‑gp, BCRP, BSEP, MATE1, or MATE2‑K) or major uptake transporters (organic anion transporting polypeptides [OATPs], organic cation transporters [OCTs], or organic anion transporters [OATs]) at therapeutic concentrations for a dose up to 5&nbsp;mg in CYP2C19 poor metabolisers and for a dose up to 15&nbsp;mg in CYP2C19 intermediate to ultra‑rapid metabolisers.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>Mavacamten is cleared from plasma primarily by metabolism through cytochrome P450 enzymes. Terminal half-life is 6&nbsp;to&nbsp;9&nbsp;days in CYP2C19&nbsp;normal metabolisers and 23&nbsp;days for CYP2C19&nbsp;poor metabolisers.</p><p>Half‑life is estimated to be, 6&nbsp;days for CYP2C19 ultra‑rapid metabolisers, 8&nbsp;days for CYP2C19 rapid metabolisers, and 10&nbsp;days for CYP2C19 intermediate metabolisers.</p><p>&nbsp;</p><p>Drug accumulation occurs with an accumulation ratio about 2‑fold for C<sub>max </sub>and about 7‑fold for AUC in CYP2C19 normal metabolisers. The accumulation depends on the metabolism status for CYP2C19 with the largest accumulation observed in CYP2C19 poor metabolisers. At steady‑state, the peak‑to‑trough plasma concentration ratio with once daily dosing is approximately&nbsp;1.5.</p><p>&nbsp;</p><p>Following a single 25&nbsp;mg dose of <sup>14</sup>C labelled mavacamten in CYP2C19 normal metabolisers, 7% and 85% of the total radioactivity was recovered in the faeces and urine of CYP2C19&nbsp;normal metabolisers, respectively. Unchanged active substance accounted for approximately&nbsp;1% and 3% of the administered dose in the faeces and urine, respectively.</p><p>&nbsp;</p><p><em><u>CYP2C19 phenotype</u></em></p><p>Polymorphic CYP2C19 is the main enzyme involved in the metabolism of mavacamten. An individual carrying two normal function alleles is a CYP2C19 normal metaboliser (e.g., *1/*1). An individual carrying two non‑functional alleles is a CYP2C19 poor metaboliser (e.g., *2/*2, *2/*3, *3/*3).</p><p>The incidence of CYP2C19&nbsp;poor metaboliser phenotype ranges from approximately&nbsp;2% in Caucasian to 18% in Asian populations.</p><p><u>&nbsp;</u></p><p><u>Linearity/non-linearity</u></p><p>Exposure to mavacamten increased approximately dose proportionally between 2&nbsp;mg and 48&nbsp;mg and is expected to result in dose proportional exposure increase across the therapeutic range of 2.5&nbsp;mg to 5&nbsp;mg in CYP2C19 poor metabolisers and 2.5&nbsp;mg to 15&nbsp;mg in CYP2C19 intermediate to ultra‑rapid metabolisers.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>No clinically significant differences in the PK of mavacamten were observed using population PK modelling based on age, sex, race or ethnicity.</p><p>&nbsp;</p><p><em><u>Hepatic impairment</u></em></p><p>A single dose PK study was conducted in patients with mild (Child-Pugh class&nbsp;A) or moderate (Child‑Pugh class&nbsp;B) hepatic impairment, as well as a control group with normal hepatic function. Mavacamten exposures (AUC) increased 3.2‑fold and 1.8‑fold in patients with mild and moderate impairment, respectively, compared to patients with normal hepatic function. There was no effect of hepatic function on C<sub>max</sub>, consistent with no change in the rate of absorption and/or volume of distribution. The amount of mavacamten excreted in urine in all 3 studied groups was 3%. A dedicated PK study has not been conducted in patients with severe (Child-Pugh class&nbsp;C) hepatic impairment.</p><p>&nbsp;</p><p><em><u>Renal impairment</u></em></p><p>Approximately&nbsp;3% of a mavacamten dose is excreted in the urine as parent substance. A population PK analysis, which comprised eGFR down to 29.5&nbsp;mL/min/1.73m<sup>2</sup>, demonstrated no correlation between renal function and exposure. A dedicated PK study has not been conducted in patients with severe renal impairment (eGFR &lt;&nbsp;30&nbsp;mL/min/1.73m<sup>2</sup>).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Toxicology findings were generally related to adverse reductions on cardiac function consistent with exaggerated primary pharmacology in healthy animals. These effects occurred at clinically relevant exposures.</p><p>&nbsp;</p><p><u>Reproductive toxicity and fertility</u></p><p>In reproductive toxicity studies, there was no evidence of effects of mavacamten on mating and fertility in male or female rats or in the viability and fertility of offspring of dams at any dose tested. However, plasma exposures (AUC) of mavacamten at the highest doses tested were less than in humans at the maximum recommended human dose (MRHD).</p><p>&nbsp;</p><p><u>Embryo-foetal and postnatal development</u></p><p>Mavacamten adversely affected embryo-foetal development in rats and rabbits. When mavacamten was administered orally to pregnant rats during the period of organogenesis, decreased mean foetal body weight, increases in post implantation loss, and foetal malformations (visceral and skeletal) were observed at clinically relevant exposures. Visceral malformations involved heart malformation in foetuses, including one total <em>situs inversus</em>, while skeletal malformations were manifested mostly as increased incidences of fused sternebrae.</p><p>&nbsp;</p><p>When mavacamten was administered orally to pregnant rabbits during the period of organogenesis, visceral and skeletal malformations were noted, consisting of malformations of the great vessels (dilatation of pulmonary trunk and/or aortic arch), cleft palate and higher incidences of fused sternebrae. Maternal plasma exposure levels (AUC) at the no effect dose level for embryo-foetal development in both species were less than those in humans at the MRHD.</p><p>&nbsp;</p><p>In a pre- and post-natal development study, administration of mavacamten to pregnant rats from gestation day&nbsp;6 to lactation/post-partum day&nbsp;20 did not result in adverse effects in the dams or offspring exposed daily from before birth (in utero) through lactation. The maternal exposure was less than the MRHD. No information is available on the excretion of mavacamten in animal milk.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Capsule content</p><p>Silica, colloidal hydrated</p><p>Mannitol (E421)</p><p>Hypromellose (E464)</p><p>Croscarmellose sodium (E468)</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Capsule shell</u></p><p><u>All strengths</u></p><p>Gelatin</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p><p><u>CAMZYOS 2.5&nbsp;mg hard capsules</u></p><p>Iron oxide black (E172)</p><p>Iron oxide red (E172)</p><p><em>&nbsp;</em></p><p><u>CAMZYOS 5&nbsp;mg hard capsules</u></p><p>Iron oxide yellow (E172)</p><p>&nbsp;</p><p><u>CAMZYOS 10&nbsp;mg hard capsules</u></p><p>Iron oxide red (E172)</p><p>&nbsp;</p><p><u>CAMZYOS 15&nbsp;mg hard capsules</u></p><p>Iron oxide black (E172)</p><p>&nbsp;</p><p><u>Printing ink</u></p><p>Iron oxide black (E172)</p><p>Shellac (E904)</p><p>Propylene glycol (E1520)</p><p>Ammonia solution, concentrated (E527)</p><p>Potassium hydroxide (E525)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at or below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Polyvinylchloride (PVC) / Polychlorotrifluoroethylene (PCTFE) / Aluminium foil blister containing 14&nbsp;hard capsules.</p><p>&nbsp;</p><p>Pack size of 14 or 28&nbsp;hard capsules.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bristol-Myers Squibb Pharma EEIG
Plaza 254
Blanchardstown Corporate Park 2
Dublin 15, D15 T867
Ireland

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aug 2024.
Approved by SFDA on 5th May 2025
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>